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ABSTRACT 
 
  
Recently, we reported a novel role for KMO in the pathogenesis of acute pancreatitis (AP). A 
number of inhibitors of kynurenine 3-monooxygenase (KMO) have previously been 
described as potential treatments for neurodegenerative conditions and particularly for 
Huntington’s disease. However the inhibitors reported to date have insufficient aqueous 
solubility relative to their cellular potency to be compatible with the intravenous (i.v.) dosing 
route required in AP. We have identified and optimised a novel series of high affinity KMO 
inhibitors with favourable physicochemical properties. The leading example is exquisitely 
selective, has low clearance in two species, prevents lung and kidney damage in a rat model 
of acute pancreatitis and is progressing into preclinical development. 
 
INTRODUCTION 
 
Acute pancreatitis (AP) is an inflammatory disease of the pancreas that is usually triggered by 
gallstones or excessive alcohol consumption.  In the majority of sufferers, symptoms resolve 
within a few days, but for approximately 20% of patients with AP, the disease progresses to 
multiple organ dysfunction syndrome (AP-MODS) requiring treatment in intensive care. The 
individual case fatality rate in AP-MODS is 21%.
1
   Currently, there is no specific therapy for 
AP-MODS and treatment is solely supportive. Until now, no disease-modifying treatments 
for AP-MODS have been identified and there are no specific treatments in routine clinical 
practice.   Therefore, it is clear that AP represents a significant unmet medical need. We have 
recently demonstrated a key role for KMO in the pathogenesis of AP-MODS.
2
 In 
experimental models of AP, mice that were genetically engineered to have absent KMO 
activity, and rats treated with a small molecule KMO inhibitor tool compound, were 
protected from AP-MODS.
2
   
  
AP patients are treated in an intensive care setting and therefore an intravenous dosing route 
is strongly preferred.  Where a fast onset of treatment is desirable, as it is in AP, initial drug 
loading with a bolus dose is advantageous to achieve the target drug plasma concentration 
rapidly.   This plasma concentration may then be maintained by infusion dosing for as long as 
required.  The initial bolus dose volume is limited in practise, to 50 mL, which in turn 
requires that the drug have high cellular potency, a significant free fraction and good 
solubility in aqueous solution at a biologically acceptable pH in order to achieve a 
therapeutically relevant free drug plasma concentration in vivo.     
For reasons of storage and dosing the stability of the compound in solution is also important, 
with a necessity for excellent solution stability at relevant pHs and to light exposure. 
A number of series of KMO inhibitors have been described
3-10 
including most recently those 
from CHDI.
3
 The majority of the molecules described share a common pharmacophore 
containing both a carboxylic acid / acidic moiety and a mono or 1,2-dichloro substitution of 
the core phenyl ring.   In our previous papers
2,11
, we have shown that one such molecule, 
3‐(5,6‐dichloro‐2‐oxo‐2,3‐dihydro‐1,3-benzoxazol‐3‐yl)propanoic acid 1 (GSK1802) 
protected animals from secondary organ dysfunction in a rat model of experimental AP.
2
 
However, the cellular potency of 1 was relatively weak so high exposures were required to 
inhibit KMO activity in vivo resulting in effects on the pathway that were not related to KMO 
inhibition. Moreover, while 1 has solubility in excess of 0.2mg/ml (Table 4), the compound 
showed significant instability precluding further development of this compound for an i.v. 
dosing modality. 
We therefore sought to expand our existing series to discover better molecules that have 
optimised characteristics that will accelerate the translation of KMO inhibitors towards the 
clinic. 
 
  
RESULTS AND DISCUSSION 
 
We first prepared a number of other analogues from the chemical series represented by 1; 
3‐(5-chloro‐6‐ethyl‐2‐oxo‐2,3‐dihydro‐1,3-benzoxazol‐3‐yl)propanoic acid 2 (GSK42811)  
retained potency in our KMO enzymatic activity assay
12
, had improved stability compared 
with the 5,6-dichloro example and had excellent aqueous solubility as the TRIS salt (>120 
mg/mL).  Further expansion of the 6-methyl group to ethyl 3 or iso-butyl 4 was also well 
tolerated, as was replacement of the methyl by a small neutral alkoxy group 5 – 10; however 
basic side chains, for example, compound 11 significantly reduced KMO inhibitory activity.  
During these changes, the activity in a cell based assay of KMO activity
2
 remained at c.a. 
1μM IC50, except for more polar side chains as in 10 where potency in the cellular assay 
declined.  The artificial membrane permeability for the compounds was low, typically at 
around or below the lower level of quantification; this was therefore not a reliable 
discriminator of cellular behaviour.   We also considered other predictors of permeability; the 
number of hydrogen bond donors and acceptors are largely unchanged for these molecules, as 
is the pKa and the molecular weights of the molecules are within a narrow distribution range.   
However, the  lipophilicity (chromLogD
13
) did correlate reasonably with the relative cellular 
activity for these and other small halogenated, alkyl and alkoxy examples and also with the 
human serum albumin (HSA) binding
14
; suggesting both HSA binding and passage of the 
compounds into the cell were largely driven by lipophilicity (Figure 1).    This is a potentially 
problematic scenario in an in vivo situation as any reduction in the target plasma free 
concentration due to increased cellular potency is likely be off-set by increased the protein 
binding so that the total plasma drug concentration required is not reduced. 
 
a) 
  
 
 
 
b) 
 
 
Figure 1 a) Drop-off from human KMOenzyme to human KMOcell pIC50 plotted against the 
Chrom LogD for examples of the series with a small 6-substituent including compounds 1 - 
12.  b)  % binding to HSA compared to Chrom LogD for the same compound set. 
  
 
Addition of a benzyloxy group at the 6-position as in 12 followed previous trends with 
modest cell activity and high HSA binding (98.3%), however its 2-pyridylmethoxy analogue 
13 showed increased KMO potency (pIC50 8.5, which is close to the tight binding limit of the 
assay), but with a significantly lower level of plasma protein binding (HSA 87.4%).  
However, this increased potency did not translate into potency in the cellular assay with 13 
having slightly weaker cellular activity than the more lipophilic 12.   
Surprisingly addition of a methyl group onto the benzylic position of 13 to give 14 resulted in 
a substantial (~30x) jump in cellular potency (pIC50 6.9) and a higher free drug fraction than 
would be expected from the logD based on the previous trends.  This substantial increase in 
cell potency was confirmed in primary human hepatocytes
2
 (pIC50 7.0).    
 
 
 
Eg. 
No. 
R Salt KMO 
mean 
pIC50 
(n) 
KMO 
LE 
/LLE 
HEK 
mean 
cell 
pIC50 
(n) 
chro
mlog
D 
pH7.4 
HS
A 
(%) 
hPPB 
(%) 
AM 
permeab
ility (nm 
/ sec ) 
1 Cl  8.2 
(6) 
0.66 / 
5.97 
5.7 
(4) 
1.61 96.3 98.2 24 
2 Me Tris 7.9 0.64 / 6.2 1.26 95.0 97.6 <3 - <10 
  
(13) 5.76 (3) (free 
acid) 
3 Et Tris 8.0 
(7) 
0.61 / 
5.33 
6.5 
(4) 
1.94 97.4 98.7 <10-22 
4 iBu Tris 7.9  
(5) 
0.54 / 
4.31 
6.1 
(3) 
3.03 99.2 nd <10 
5 OMe - 7.9 
(8) 
0.60 / 
6.43 
5.3 
(2) 
nd 89.0 nd <3 
6 OEt Tris 8.3 
(5) 
0.60 / 
6.30 
6.4 
(7) 
1.49 88.7 95.8 <10 
7 OcPr Tris 8.5 
(5) 
0.58 / 
6.45 
5.9 
(8) 
1.64 94.3 96.9 15 
8 OCH2cPr Tris 8.0 
(5) 
0.52 / 
5.56 
5.8 
(11) 
2.09 96.2 96.0 19 
9 OCH2cBu Tris 7.6 
(2) 
0.47 / 
4.60 
5.9 
(2) 
2.90 98.1 98.1 12 
10 O(CH2)2OMe Tris 7.5 
(5) 
0.49 / 
6.14 
4.3 
(5) 
0.88 44.2 70.7 <3 
11 O(CH2)2pyrrolid
in-1-yl 
Tris 6.1 
(5) 
0.35 / 
6.13 
nd -0.26 15.1 nd <3 
12 OBn Tris 7.6 
(5) 
0.43 / 
4.37 
5.8 
(2) 
2.71 98.3 nd nd 
13 OCH2pyrid-2-yl Tris 8.5 
(7) 
0.49 / 
6.76 
5.3 
(11) 
1.32 87.4 
 
92.6 11 
14 OCH(Me)pyrid- Tris 8.5 0.47 / 6.9 1.86 87.1 81.7 <3 
  
2-yl (7) 6.45 (9) 
15 (R)-
OCH(Me)pyrid-
2-yl 
Tris 8.6 
(12) 
0.47 / 
6.55 
6.7 
(15) 
1.71 93.3 88.1 <3-20 
16 (S)-
OCH(Me)pyrid-
2-yl 
Tris 6.6 
(7) 
0.36 / 
4.55 
4.2 
(3) 
1.79 91.6 nd <3 
17 (R)-
OCH(Me)oxazol
-2-yl 
Tris 8.5 
(5) 
0.49 / 
7.28 
5.1 
(3) 
1.11 77.3 nd <3 
18 (R)-
OCH(Me)pyrimi
din-2-yl 
Tris 8.3 
(5) 
0.45 / 
7.21 
5.5 
(3) 
0.83 59.1 nd <3 
19 (R)-
OCH(Me)pyrida
zin-3-yl 
- 8.9 
(5) 
0.49 / 
8.08 
6.2 
(3) 
0.83 
 
59.1 68.1 <3 
20 (R)-OCH(Me)-
4-
methylpyridin-
2-yl 
Tris 8.4 
(5) 
0.44 / 
5.85 
4.5 
(2) 
2.15 94.4 nd <3 
21 (R)-OCH(Me)-
5-
methylpyridin-
2-yl 
Tris 8.5 
(6) 
0.45 / 
5.95 
8.2 
(12) 
2.02 nd 97.8 22 
22 (R)-OCH(Me)- Tris 8.5 0.45 / 7.0 2.65 97.9 99.0 60 
  
5-chloropyridin-
2-yl 
(6) 5.66 (3) 
23 (R)-OCH(Me)-
5-fluoropyridin-
2-yl 
Tris 8.6 
(3) 
0.45 / 
6.33 
7.6 
(9) 
1.98 94.0 nd 31 
24 (R)-OCH(Me)-
6-
methylpyridin-
2-yl 
Tris 8.3 
(5) 
0.44 / 
5.75 
6.5 
(6) 
2.12 93.2 nd 21 
Table 1 
 
The X-ray crystal structure of human KMO has not been reported. However KMO from the 
bacterium Pseudomonas fluorescens (Pf KMO) shows high levels of similarity to the human 
protein in the active site. All the residues directly lining the active site are conserved with 
human KMO, except His320 in Pf KMO which is a phenylalanine in human.  
Modelling of these compounds based on the X-ray structure previously described for 1 in Pf 
KMO
2
, gave a good fit of the smaller alkoxy groups into the available space around the 6-
position, but the larger alkoxy and in particular the benzyl and pyrid-2-ylmethyl examples 12 
and 13 could only be modelled into a pocket formed by Asn54, Glu195, Thr234 and Thr236 
with displacement of the resident waters.  This gave no explanation of the potency jump seen 
for 13 as the nitrogen of the pyridine appeared to make no additional contacts.   
We were able to obtain a crystal structure of 14 in Pf KMO (Figure 2).  The crystal structure 
showed only the R-enantiomer 15 bound into the active site, with the pyridyl moiety 
occupying an unexpected binding mode (Figure 2).   In the X-ray structure of 14 / 15, the 
bicyclic core and acid side chain are bound as we had seen previously for 1, although as with 
  
1 the exact interactions of the carboxylic acid vary between the A and B chains in the crystal 
structure (a direct hydrogen bond between carboxylate and Tyr98 hydroxyl in the A chain 
and a water mediated hydrogen bond in the B chain).  However the tricyclic group of the 
catalytic FAD has rotated to accommodate 15, allowing the (R)-1-(pyridine-2-yl)ethoxy to sit 
underneath forming a face to face π interaction between the pyridine of 15 and FAD.  The 
pyridine nitrogen makes H-bonding interactions with a water network extending towards 
Pro318 and Val317, whilst the pyridine ring in addition to the face to face π interaction with 
FAD also forms two edge to face π interactions from the 5-position of the pyridine into 
Tyr193, and from Phe238 into the face of the pyridine ring. 
A similar binding mode for the S-enantiomer 16 would result in obvious protein clashes, and 
indeed this compound is much less potent.  
  
Whilst there is high homology between the Pf KMO and human KMO and the SAR from the 
human KMO is consistent with the Pf KMO crystal structures, these structures and the FAD 
movement must be interpreted with some caution. 15 inhibited Pf KMO with a similar 
potency as the human enzyme (Pf KMO pIC50 8.5, h KMO pIC50 8.6), however the h KMO 
potency may be an underestimate as we are close to the tight binding limit of the assay. 
 
Subsequent crystal structures on a small set of intermediately sized inhibitors 6, 7 and 9, 
showed 6 and 7 to bind in the same mode as 1 with the side-chain accommodated into a space 
in front of the FAD tricycle.  9 however shows significant differences in binding mode in the 
A and B chains of the protein crystal structure (Figures 3a / 3c).  In the A chains, where the 
ligand carboxylic acid is directly H-bonded to Tyr98, the protein environment around the 
ligand alkyl groups is the same, including the position of the FAD tricycle. The different 
  
sized alkyl groups are accommodated by small adjustments in the inhibitor bicycle position, 
with the largest, cyclobutyloxy, group adjacent to the FAD in a perpendicular position. 
For the B chains, where the carboxylic acid is bonded to Tyr98 through a water molecule, the 
protein environment around the ligand alkyl groups is the same for the ethyl and cyclopropyl 
groups as in the three A chain structures, however the cyclobutyl group induces a change in 
the orientation of the FAD tricycle, and by changing its own conformation by approximately 
90° it is able to adopt a conformation parallel to the FAD aromatic ring. This is the first 
example of the FAD tricycle adopting an intermediate conformation between the two 
extremes seen with 1 and 14/15 (Figure 3c, d). Although 9 is able to cause a change in FAD 
tricycle conformation, in this case it has a lower potency than 6 and 7, suggesting that the 
conformational change results in overall less favourable interactions in the KMO active site. 
It appears that only when the larger and planar pyridyl group of 14/15 is present can the FAD 
tricycle achieve the full positional shift required to allow the favourable aromatic -stacking 
and edge to face  interactions to be made. 
 
 
  
 
Figure 2 Crystal structures of 1 (orange) and 14/15 (green) bound to Pf KMO protein (A 
Chain).  The tricycle of the catalytic FAD has rotated in the structure of 14 to accommodate 
the pyridine. 
a b 
  
c d 
  
 
Figure 3 a, b Comparison of binding modes of 9 (blue) with 6 (gold) and 7 (magenta) 
bound to Pf KMO in the A chain (a) and in the B chain (b). In the A chain, the largest, 
cyclobutyl, group shifts the inhibitor slightly towards Tyr98. In contrast, in the B chain, 
whilst the FAD is twisted upon binding of the cyclobutyl substitutent, there is very little 
difference in the actual positions of the inhibitor bicycles. c, d Comparison of binding 
modes of 1 (orange), 9 (blue) and 14/15 (green) bound to Pf KMO in the B chain 
exhibiting the three different observed FAD conformations. (c) front view (d) side view. 
 
  
 
Three approaches were taken to further improve on 15 based on knowledge from the crystal 
structure: to modify the 1-(pyridine-2-ylethoxy) side chain, to substitute the pyridine ring and 
to explore alternative bicyclic cores. 
 
Analogues where the pyridine was replaced by an alternative heteroaromatic (17 – 19) 
retained potent enzyme inhibition but had weaker cell potency, possibly due to a potentially 
negative impact of the additional polarity on cell permeability, although this was not 
confirmed. As expected the increased polarity correlated with lower protein binding.  
 
From the crystal structure of 15 bound to Pf KMO, it was hypothesised that substitution of 
the pyridine would be tolerated at any of the 4-, 5- and 6-positions, but that a 5-position 
substituent would have the potential to form an interaction with the π cloud of Tyr193. 
Substitution at the 3-position was excluded as being likely to clash with the α-methyl group 
in the exemplified binding mode.  In the KMO primary assay, substitution of the pyridine 
appeared to be tolerated at all of these positions, but only substitution at the 5-position was 
beneficial in the cell with 21, 22 and 23, all having enhanced cell potency compared with 15. 
 
The 1-(pyridin-2-ylethoxy) was introduced onto a number of 6/5 and 6/6 cores, including 
some which we had previously examined
11
  and in others chosen based on the crystal 
structures we had generated (Table 2).  All examples demonstrated KMO pIC50s at around 
the theoretical tight binding limit of the KMO enzyme assay.   The cellular potency was 
generally higher than for 15 with the exception of the indazole 27.  The benzisoxazole 28 was 
of particular interest with an approximately 60-fold increase in cell potency over 15, although 
with a ~5-fold reduced free fraction (2.2% vs 11.9%).  This cellular activity was confirmed in 
  
primary human hepatocytes
1
 (pIC50
 
8.0).  The thioheteroaryl 29 was also very potent with a 
HEK cell pIC50 of 7.5. 
 
 
Eg. No. PQR Salt KMO mean 
pIC50 (n) 
HEK 
mean cell 
pIC50 (n) 
chromlog
D 
pH 7.4 
hPPB 
(%) 
15 OC(=O)-N Tris 8.6 (12) 6.7 (15) 1.71 88.1 
25 OCH2-C(=O)-N Tris 8.3 (6) 7.2 (11) 1.56 92.5 
26 CH=CH-N - 8.3 (5) 7.6 (2) 2.17 nd 
27 CH=N-N Tris 8.5 (5) 7.1 (5) 1.70 90.1 
28 O-N=C Tris 8.3 (7) 8.5 (12)   1.99 97.8 
29 S-C(=O)-N - 8.7 (5) 7.5 (1) 1.81 nd 
Table 2 
 
Translation of the substituted pyridines onto the more potent benzisoxazole core gave some 
extremely cell potent examples (30, 31, 32), although with lower free fractions than the less 
lipophilic benzoxazolones (Table 3).  The (6-methylpyridazin-3-yl)ethoxy example 33 was 
also prepared on the benzisoxazole core,  aiming to combine the large free fraction of 19 with 
the more lipophilic core and the additional methyl substituent (as in 30) to achieve a logD 
consistent with good cellular potency.  This combination, as desired, gave enhanced cellular 
  
activity (pIC50 8.5) and a higher plasma free fraction than the equivalent pyridine 30 (7.1% vs 
0.7%). 
 
 
Eg. 
No. 
Ar R Salt KMO 
mean 
pIC50 (n) 
HEK 
mean 
cell 
pIC50 
(n) 
chromlog
D 
pH 7.4 
HSA 
(%) 
hPPB 
(%) 
30 5- 
methylpyridi
n-2-yl 
Me Tris 8.5 (6) 
(30a HCl 
salt) 
8.8 (5)  2.42  98.4 99.7  
31 5- 
chloropyridin
-2-yl 
Me Tris 8.5 (5) 8.4 (4) 2.91 99.0 99.8 
32 5- 
fluoropyridin
-2-yl 
Me - 8.5 (9) 7.5 (6) 2.47 98.3 nd 
33 6-
methylpyrida
zin-3-yl 
Me - 8.7 (4) 8.5 (19) 2.97 89.2 92.9 
Table 3 
 
  
The enhanced cellular activity of 14 and later analogues compared with the smaller alkyl 
examples and 12 /13 and movement of the FAD in Pf KMO led us to examine the kinetics of 
interaction between these molecules and hKMO in an attempt to understand the increase in 
potency.  We had previously shown that 2 had a fast dissociation rate. These kinetics of 
interaction of a range of inhibitors with human KMO were studied and are reported in detail 
elsewhere.
15
 In “recovery of activity” experiments 13 was found to have a dissociation T1/2 in 
the region of 30min and a Ki in the order of 1nM, whereas the T1/2 of 15 was ~2h and its Ki is 
approximately 100pM. For 28 the association kinetics were measured in onset of inhibition 
time-courses using the mass spectrometry assay.  Observed rate constants increased linearly 
with [28], indicative of second order kinetics, with kon = 6.2 x 10
5
 M
-1
 s
-1
. Due to the high 
potency of 28, the recovery of activity approach could not be used to measure koff. Instead the 
time-course was analysed by numerical fitting to a model of competitive inhibition with kon 
fixed at 6.2 x 10
5
 M
-1
s
-1
, giving a value of koff = 1.94 x 10
-5
 s
-1
. The calculated Ki of 28 is thus 
50pM and the T1/2 was around 10h.    
 
A number of the small alkoxy examples 1, 2, 6, 7, 8, chiral pyridyls 15, 28, 30 and the chiral 
pyridazinyl 33 were profiled in i.v. rat DMPK
16
 (Table 4) and for stability to light and pH 
under oxidative and non-oxidative conditions and for solubility in saline.  The examples with 
a small alkyl or alkoxy substituent had a small volume of distribution, low to moderate 
clearance and, except for 1 and 2, a short half-life.  By contrast 15 had a long half-life and a 
much higher volume of distribution.  The pyridyl benzisoxazole examples, 28, 30 and 31 had 
low volumes and clearance with moderate to long half lives, whereas pyridazinyl example 33 
had a slightly higher volume, moderate clearance and moderate T1/2. 
 
Eg. No. rPPB Rat i.v.dmpk (~1 mg/kg) Stability  Saline 
  
(%) solubility 
  T1/2 (h) Clb 
(mL/
min/k
g) 
Vdss 
(l/kg) 
pH6 
oxidative 
(T1/2) 
Light (% 
remaining 
at 12h) 
24 h   
(ug/mL) 
1 91.7 4.3 4.3 0.28 334 h  41 270  
2 95.5 3.7 4.7 0.52 >1000 h 100 >127000 
6 81.6 0.43 16.0 0.36 >1000 h 99.5 >1880 
7 90.3 0.39 9.4 0.29 >1000 h 100 >2400 
8 90.2 0.68 4.1 0.26 >1000 h 104.9 >2060 
15 78.5 5.6 16.8 2.96 >1000 h 99.2 >9500 
28 97.8 6.6 0.8 0.42 >1000 h 97.7 >7440 
30 99.1 3.6 1.1 0.31 >1000 h 96.5 >860 
31 99.7 8.7 0.35 0.26 >1000 h 99.5 >620 
33 93.3 1.5 12.0 1.10 >1000 h 85.2 230 
Table 4 
 
All examples showed excellent stability to both light and relevant pH and all had good levels 
of solubility in saline, particularly as the TRIS salts.  We had identified the TRIS salt as a 
means of significantly improving the aqueous solubility of the smaller alkyl / alkoxy 
substituted molecules including 2 and for these the TRIS salts were well behaved solids.  
However, for molecules containing a chiral pyridine or chiral heteroaryl side chain, the TRIS 
salts were hygroscopic gums.  We therefore returned to preparing the free acid for later 
examples and compound batches. 
 
  
Following consideration of all available data compound 28 was chosen for further profiling. 
This compound showed no inhibitory effects on the other enzymes in the tryptophan 
metabolism pathway (IDO, TDO, KATI / II, kynureninase) and had remarkable selectivity in 
GSK’s liability panel (57 assays) with a window of >20,000 fold over all the targets 
examined.   
 
Compound 28 was evaluated in a rat PK/PD study using a loading i.v. bolus followed by a 3h 
i.v. infusion formulated as the ethanolamine salt formed in-situ in the dosing vehicle. The 
potency of 28 against rat KMO was lower than observed with human enzyme. When rat 
KMO was expressed in HEK cells the apparent cellular Ki was calculated as (45nM) and so 
three dose levels were tested that delivered steady free drug levels ranging from 10x above to 
10x below this level (Table 5).  28 had no impact on circulating TRP levels, but showed a 
dose dependent effect on the concentration of 3-hydroxykynurenine (the product of KMO) 
and a corresponding increase in kynurenine (the substrate of KMO), with a half maximal 
effect at concentrations around the rat cell Ki (Figure 6). As expected, dose dependent 
increases were also observed in the diversionary products of kynurenine metabolism – 
kynurenic acid and anthranilic acid – consistent with the effects previously reported.2  
  
Dose of 28 (free acid) Free plasma 
concentration 
Concentration relative to 
cellular Ki 
0.025mg/kg & 0.0025mg/kg/hr 
  
3nM 0.07x 
0.25mg/kg & 0.025mg/kg/hr 
  
50nM 1.1x 
2.5mg/kg & 0.25mg/kg/hr  405nM 9.0x 
  
 
Table 5 
 
 
  
Figure 6 a) Effect of 28 on components of the kynurenine pathway measured at 3hrs after 
initiation of dosing with doses of 2.5mg/kg bolus & 0.25mg/kg/hr infusion (high), 0.25mg/kg 
bolus & 0.025mg/kg/hr infusion (med) and 0.025mg/kg bolus & 0.0025mg/kg/hr infusion 
(lo) doses (Table 5).  
 
Compound 28 was assessed in an experimental model of AP in rats
17 
dosing as an initial 20 
mg/kg bolus followed by a 5h, 2.2 mg/kg/hr infusion therapeutically, commencing 1 hour 
after the induction of AP.  This regime delivered free concentration in plasma of 50x the 
pIC50 for rat KMO, and resulted in a decrease in 3-hydroxykynurenine and an increase in 
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kynurenine as expected (Figure 7). The extent of pancreatic injury in this model (measured 
by serum amylase levels) was only marginally impacted by treatment with 28. The stress 
response during experimental AP-MODS caused a decrease in plasma glucose concentration, 
which was less pronounced in rats with AP treated with 28. Importantly, 28 showed 
significant protective effects against the secondary organ injury to lung as assessed by 
histology and measured by analysing protein leak into the alveolar space (in bronchoalveolar 
lavage fluid). Furthermore, kidney injury was reduced with 28 treatment, measured by a 
reduction in AP-induced plasma creatinine rise and a reduction in apoptotic cell count in the 
outer medullary stripe of the kidney assessed by TUNEL staining (Figure 7).  
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Figure 7 a) Reduced plasma levels of 3-HK and increased levels of kynurenine compared 
with both sham operated and AP control animals at 5 hours after start of administration of 28.  
b) Therapeutic administration of 28 1 hour after the induction of experimental AP in rats 
protects against secondary organ damage in lung and kidney. Each point represents data from 
an individual rat, with group sizes as follows: sham n=5, AP n=6, AP + 28 n=7. For the lung 
TUNEL figure panel, one extreme outlier data point was omitted from the sham group and 
one extreme outlier from the AP + 28 group after careful consideration. Both excluded data 
points were at least 7x standard deviations from the mean of the remainder of the 
corresponding group and were felt to be due to technical error. Statistical comparison 
between groups was by one-way ANOVA with post-hoc Student-Neuman-Keuls, *P < 0.05. 
c) Lung histology representative photomicrographs. Haematoxylin and eosin staining of 
formalin-fixed sections of lung tissue. Alveolar-epithelial thickening and inflammatory 
infiltrates are visible on images in the AP group, which is less marked in the AP + 28 group.  
 
Dog i.v. infusion PK
18
 of the free acid of 28 dosed at 1 mg/kg showed a similar profile to rat 
i.v. PK with long half-life and low volume and clearance (Dog: T1/2 5.8h, Vd 0.36, Clb 0.93). 
Based on scaling of PK parameters from rat and dog, combined with the high cellular potency 
and moderated free fraction, we estimate that a daily dose of less than 50mg should provide 
substantial suppression of 3-hydroxykynurenine levels in man.  
 
SYNTHESIS 
The synthesis of 1 and 2 have been described previously
2/19
 and examples 3 to 7 were 
prepared using the same synthetic sequence (Scheme 1).  The benzo[d]oxazol-2(3H)-ones 
  
35a – g were prepared by cyclisation of the relevant 2-aminophenol (34a-g) using either CDI 
or triphosgene.  The bicyclic product 35a-g was then alkylated with 3-bromopropanoic acid 
and the target molecule was then optionally converted to the TRIS salt in aqueous methanol 
or ethanol. 
 
 
Scheme 1  
(i) CDI, THF, 60 - 80 °C  or Triphosgene, Et3N, 0°C – rt (ii) 3-bromopropanonic acid, K2CO3, MeCN, 60 - 80 
°C (iii) TRIS, EtOH or MeOH, H2O, 80 °C. 
 
The remaining alkoxy substituted examples 8 to 24 were prepared as shown in Scheme 2 
from  the commercially available 6-bromo-5-chlorobenzo[d]oxazol-2(3H)-one  36.  This was 
alkylated with methyl 3-bromopropanoate to give 37.  Treatment of 37 with 
bis(pinacolato)diboron and palladium catalysis give the pinnacolborane 38 which was 
converted to the phenol 39 with hydrogen peroxide.   The 6-alkoxy group was installed either 
under Mitsonubu conditions with the alcohol or by alkylation using either the appropriate 
bromide or an activated alcohol.  Acid mediated hydrolysis of the esters 40a-o was generally 
preferred to avoid ring opening, which gave the target compounds 8 to 24. 
 
  
 
Scheme 2  
(i) methyl 3-bromopropanoate, K2CO3, MeCN, 70 °C (ii) bis(pinacolato)diboron, PdCl2(dppf), KOAc, dioxane, 
100 °C (iii) 30% H2O2, AcOH, THF, rt (iv) ROH, DEAD, PPH3 or RX / ROMs, K2CO3 (v) 0.5 N HCl, dioxane, 
80 °C or 6N HCl 70-100 °C or LiOH, dioxane, 0 °C - rt (vi) TRIS, MeOH, rt. 
 
Compound 25 was synthesised in a similar manner to the equivalent benzoxazolone from 7-
bromo-6-chloro-2H-benzo[b][1,4]oxazin-3(4H)-one 42, but using acrylonitrile in place of 
methyl 3-bromopropionate for the alkylation which installs the side chain  (Scheme 3).  The 
nitrile 43 was converted to the ester 44 by hydrolysis with hydrochloric acid in methanol, 
before conversion of the 7-bromo to the 7-phenol 46 via the pinnacol borane 45.  A 
subsequent Mitsonubu coupling and ester hydrolysis gave 25.  
  
 
 
Scheme 3  
(i) 2-chloroacetyl chloride, KOAc, DMF, rt (ii) acrylonitrile, K2CO3, MeCN, 70 °C (iii) c. HCl, MeOH, 90 °C 
(iv) bis(pinacolato)diboron, PdCl2(dppf), KOAc, dioxane 100 °C, Ar (v) H2O2, AcOH, THF, rt (vi) (S)-1-(pyrid-
2-yl)ethanol, PPh3, DEAD, toluene, rt (vii) 0.5N HCl, dioxane, 80 °C. 
 
The choice of alkylation conditions was found to be highly sensitive to the core bicyclic, for 
6-chloro-5-methoxy-1H-indole 48, ethyl acrylate was preferred as the alkylating group 
(Scheme 4).  Conversion of the 5-methoxy indole 49 to the 5-phenol 50 was followed by a 
Mitsonubu coupling and ester hydrolysis to give 26. 
  
 
Scheme 4  
(i) ethyl acrylate, K3PO4, MeCN, rt (ii) AlCl3, toluene, 100 °C (iii) (S)-1-(pyrid-2-yl)ethanol, PPh3, DEAD, 
toluene, rt (iv) LiOH, THF, H2O, rt. 
 
Commercially available 5-bromo-6-chloroindazole 52 was also alkylated with ethyl acrylate 
to give ester 53.  This was then converted from the 5-bromo compound in the same manner as 
the analogous benzoxazolone to give compound 27.  
 
Scheme 5 
 (i) ethyl acrylate, DBU, MeCN, rt (ii) bis(pinacolato)diboron, PdCl2(dppf), KOAc, dioxane 100 °C, Ar (iii) 
H2O2, THF, AcOH, rt (iv) (S)-1-(pyrid-2-yl)ethanol, PPh3, DEAD, toluene, rt (v) LiOH, THF, H2O, rt. 
 
  
The benzisoxazole core can be synthesised by several routes
20
, the shorter improved route is 
shown in Scheme 6.  Acid 57 was converted to the ester with thionyl chloride and methanol 
and then the methoxyl adjacent to the ketone was selectively demethylated with aluminium 
trichloride and sodium iodide to give phenol 59.  The ketone was converted to the 
hydroxylamine with ammonium hydroxide and the isoxazole closed by heating in a mixture 
of acetic anhydride and pyridine.  Demethylation of 61 using aluminium chloride gave phenol 
62.   This was then converted to ether 64a-d by addition of the chiral pyridine alcohol 63a 
under Mitsonubu conditions or by alkylation with the relevant mesylate 63b-d.  Subsequent 
lithium hydroxide hydrolysis of the esters gave compounds 28, 30, 31, 32 and 33. 
 
  
 
Scheme 6  
 (i) SOCl2, MeOH, 0 °C - rt (ii) NaI, AlCl3, MeCN, 80 °c (iii) pyridine, MeOH, NH2OH.HCl, 100 °C (iv) 
pyridine, Ac2O, 110 °C to 120 °C,  (v) AlCl3, DCM, rt (vi) 63a: ROH, PPh3, DEAD, THF or 63b-d: ROMs, 
K2CO3, DMF or MeCN, 70 - 80 °C (vii) LiOH, THF, H2O, MeOH or EtOH, 0 °C - rt 
 
The 5-chloro-6-methoxybenzo[d]thiazol-2(3H)-one 66 was prepared from the 5-chloro-6-
methoxybenzo[d]thiazol-2-amine 65 by diazotization and treatment with acetic acid (Scheme 
7).    Alkylation with ethyl acrylate and demethylation with boron tribromide gave phenol 68.  
  
Treatment of 68 with the mesylate of the chiral pyridine under alkylation conditions and 
subsequent acid mediated hydrolysis of the ester 69 gave 29.  
 
 
 
Scheme 7  
 (i) HCO2H, AcOH, c. HCl, NaNO2, H2O,  -10 - 100 °C (ii) ethylacrylate, Si(OEt)4, CsF, toluene, 110 °C (iii) 
BBr3, DCM, rt (iv) (S)-1-(pyrid-2-yl)ethanol, PPh3, DEAD, toluene, rt (v) 0.5N HCl, dioxane, 90 °C. 
 
CONCLUSION 
We report here the development and optimisation of a series of KMO inhibitors arising from 
a Discovery Partnership with Academia collaboration between the University of Edinburgh 
and GSK. Using novel Pf KMO crystal structures, we have rationalised some unexpected 
SAR on the human KMO enzyme. This has enabled further optimisation using the principles 
of structure-driven design to generate molecules with very high KMO inhibitory potential.  In 
the process we have also converted the series from compounds with a rapid off-rate (2) to 
examples with very slow dissociation kinetics (15, 28).  The resulting molecules have potent 
cellular activity, excellent aqueous solubility and a DMPK profile suitable for i.v. dosing. 
The effect on plasma concentrations of kynurenine pathway metabolites after administration 
of 28 recapitulates the previously observed effect using tool KMO inhibitor compounds and 
  
Kmo knockout mice.
2
 The effect on the kynurenine pathway in vivo and at pharmacologically 
active doses is devoid of the non-KMO mediated effects (reduction in TRP, large increase in 
KYNA) previously observed with 1.
2 
Compound 28 showed protection against 
extrapancreatic tissue injury to kidney and lung during experimental AP in rats. Compound 
28 will now be progressed towards clinical evaluation. 
 
EXPERIMENTAL SECTION 
 
General Experimental Details.  All commercial reagents and solvents were obtained from 
commercial sources and used without further purification.  LC/MS was conducted on a 
number of systems for which details are provided in the supplementary data. 
1
H NMR spectra, chemical shifts are given in ppm (δ) relative to tetramethylsilane (TMS) 
as an internal standard.  Purity of the final compounds was of >95% using interpretation of a 
combination of LCMS and NMR data unless stated otherwise. 
 
3‐(5,6‐Dichloro‐2‐oxo‐2,3‐dihydro‐1,3-benzoxazol‐3‐yl)propanoic acid (1) was prepared as 
described in reference 2. 
 
 2-Amino-2-(hydroxymethyl)propane-1,3-diol 3‐(5‐chloro‐6‐methyl‐2‐oxo‐2,3‐dihydro‐1,3-
benzoxazol‐3‐yl)propanoic acid (2) was prepared as described in reference 19. 
 
2‐Amino‐2‐(hydroxymethyl)propane‐1,3‐diol; 3‐(5‐chloro‐6‐ethyl‐2‐oxo‐2,3‐dihydro‐1,3-
benzoxazol‐3‐yl)propanoic acid (3).  5-Chloro-6-ethyl-2,3-dihydro-1,3-benzoxazol-2-one  
36c (475 mg, 2.41 mmol), 2-bromopropanoic acid (443 mg, 2.89 mmol) and potassium 
carbonate (665 mg, 4.82 mmol) were mixed in acetonitrile (10 mL) and stirred at 75 °C for 
  
14 h.  The cooled mixture was treated with hydrochloric acid (0.5N) until the mixture 
achieved a pH of between 2 and 4.  The solvent was evaporated and the residue purified by 
preparative HPLC eluting with an acetonitrile / water gradient (45 – 50%) containing TFA 
(0.1%) to give 3‐(5‐chloro‐6‐ethyl‐2‐oxo‐2,3‐dihydro‐1,3-benzoxazol‐3‐yl)propanoic acid 
(180 mg, 20%).   A portion of this material (150 mg, 0.56 mmol) and 
2‐amino‐2‐(hydroxymethyl)propane‐1,3‐diol (68 mg, 0.56 mmol) were mixed in ethanol (9 
mL) and water (3 mL) and the mixture stirred at room temperature for 1 h.  The solvents were 
removed under reduced pressure to give the title compound as an off-white solid (218 mg, 
100 %).  
1
H NMR (CD3OD) 7.37 (s, 1H), 7.17 (s, 1H), 4.06 (t, J = 7.2Hz, 2H), 3.65 (s, 6H), 
2.77 (q, J = 7.4, 2H), 2.60 (t, J = 7.1, 2H), 1.21 (t, J = 7.5, 2H).  LCMS:  MH+ 268 / 270, 
retention time 1.55 min (method B). 
 
2‐Amino‐2‐(hydroxymethyl)propane‐1,3‐diol; 3‐[5‐chloro‐6‐(2‐methylpropyl)‐2‐oxo‐2,3‐ 
dihydro‐1,3‐benzoxazol‐3‐yl]propanoic acid (4).  5-Chloro-6-(2-methylpropyl)-2,3-dihydro-
1,3-benzoxazol-2-one  36d (200 mg, 0.88 mmol), 2-bromopropanoic acid (153 mg, 1.06 
mmol) and potassium carbonate (138 mg, 0.88 mmol) were mixed in acetonitrile (10 mL) and 
stirred at 80 °C for 2 h.  Water was added and the pH of the mixture adjusted to pH 7 by 
addition of ammonium chloride.  The mixture was extracted with ethyl acetate, the organics 
dried over sodium sulphate and the solvent evaporated in vacuo.  The residue was purified by 
preparative HPLC eluting with acetonitrile / water (55: 45) containing 0.1% TFA to give 
3‐[5‐chloro‐6‐(2‐methylpropyl)‐2‐oxo‐2,3‐ dihydro‐1,3‐benzoxazol‐3‐yl]propanoic acid (45 
mg, 17%).   This material and 2‐amino‐2‐(hydroxymethyl)propane‐1,3‐diol (18 mg, 0.15 
mmol) were mixed in methanol (3 mL) and water (3 mL) and the mixture stirred at room 
temperature for 1 h.  The solvents were removed under reduced pressure to give the title 
compound as a yellow oil (63 mg, 100 %).  
1
H NMR (CD3OD) 7.39 (s, 1H), 7.12 (s, 1H), 
  
4.06 (t, J = 7.2Hz, 2H), 3.65 (s, 6H), 2.62 (m, 4H), 1.95 (m, 1H), 0.93 (d, J = 6.8, 6H).  
LCMS:  MH+ 296, retention time 1.66 min (method B). 
 
3‐(5‐Chloro‐6‐methoxy‐2‐oxo‐2,3‐dihydro‐1,3‐benzoxazol‐3‐yl)propanoic acid (5).  
5‐Chloro‐6‐methoxy‐2,3‐dihydro‐1,3‐benzoxazol‐2‐one 36e (150 mg, 0.75 mmol) in 
acetonitrile (10 mL) were added 2-bromopropanoic acid (115 mg, 0.75 mmol) and potassium 
carbonate (138 mg, 1.5 mmol) and the mixture stirred at 60 °C for 2 h.  The solvent was 
evaporated and the residue adjusted to pH 4 by addition of hydrochloric acid (1 N).  The 
mixture was extracted with ethyl acetate (3x 15 mL) and the combined organics dried over 
sodium sulphate.  The residue was purified by chiral SFC (CO2 / methanol containing 0.1 % 
TFA) to give the title compound as a white solid (60 mg, 29 %).  
1
H NMR (CD3OD) 7.39 (s, 
1H), 7.16 (s, 1H), 4.08 (t, J = 6.7Hz, 2H), 3.89 (s, 3H), 2.76 (t, J = 6.2Hz, 2H).  LCMS:  MH+ 
272, retention time 1.37 min (method C). 
 
2‐Amino‐2‐(hydroxymethyl)propane‐1,3‐diol; 3‐(5‐chloro‐6‐ethoxy‐2‐oxo‐2,3‐dihydro‐1,3‐ 
benzoxazol‐3‐yl)propanoic acid (6).  A mixture of 
5‐chloro‐6‐ethoxy‐2,3‐dihydro‐1,3‐benzoxazol‐2‐one 36f (150 mg, 0.70 mmol), 2-
bromopropanoic acid (107 mg, 0.70 mmol) and potassium carbonate (97 mg, 0.7 mmol) in 
acetonitrile (10 mL) was heated at 80 °C for 16 h.  The reaction mixture was diluted with 
water and acidified with hydrochloric acid.  The mixture was extracted with ethyl acetate, the 
organic phase washed with water (3x 30 mL) and dried over sodium sulphate.  The solvent 
was evaporated in vacuo and the residue purified by preparative HPLC (acetonitrile / water 1: 
1, including 0.1% TFA) to give 3‐(5‐chloro‐6‐ethoxy‐2‐oxo‐2,3‐dihydro‐1,3‐benzoxazol‐ 
3‐yl)propanoic acid (38 mg, 19%).  This material was treated with 
2‐mino‐2‐(hydroxymethyl)propane‐1,3‐diol (16 mg, 0.133 mmol) in methanol (5 mL) and 
  
water (6 mL) and the mixture stirred for 1 h.  The solvents were evaporated in vacuo to give 
the title compound as a yellow solid (54 mg, 100%).  
1
H NMR (CD3OD) 7.37 (s, 1H), 7.05 
(s, 1H), 4.02 (m, 4H), 3.57 (s, 6H), 2.54 (m, 2H), 1.38 (3H, m).  LCMS:  MH+ 284, retention 
time 1.43 min (method B).  
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-(5-chloro-6-cyclopropoxy-2-oxo-2,3-
dihydro-1,3-benzoxazol-3-yl)propanoic acid (7).  A mixture of 5-chloro-6-cyclopropoxy-2,3-
dihydro-1,3-benzoxazol-2-one 36g (183 mg, 0.81 mmol), 2-bromopropanoic acid (149 mg, 
0.98 mmol) and potassium carbonate (224 mg, 1.62  mmol) in acetonitrile (5 mL) was heated 
at 73 °C for 14 h.    The reaction was cooled to room temperature and acidified to between 
pH2 and pH4 with hydrochloric acid (0.5 N).  The solvent was removed and the residue 
purified by preparative HPLC eluting with an acetonitrile / water gradient containing 0.1 % 
TFA (35-45 % acetonitrile) to give  3-(5-chloro-6-cyclopropoxy-2-oxo-2,3-dihydro-1,3-
benzoxazol-3-yl)propanoic acid as a white solid (70 mg, 29 %).  This material was treated 
with 2-amino-2-(hydroxymethyl)propane-1,3-diol (28.5 mg, 0.24 mmol) in ethanol (3 mL) 
and water (1 mL) at room temperature for 0.5 h.  The solvent was evaporated to give the title 
compound as a white solid (48.5 mg, 100 %). 
1
H NMR (CD3OD) 7.38 (s, 1H), 7.37 (s, 1H), 
4.04 (t, J = 7.2Hz, 2H), 3.86 (m, 1H), 3.64 (s, 6H), 2.59 (t, J = 7.1, 2H), 0.86 – 0.73 (m, 4H).  
LCMS:  MH+ 286 / 288, retention time 1.51 min (method B).  
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-[5-chloro-6-(cyclopropylmethoxy)-2-oxo-
2,3-dihydro-1,3-benzoxazol-3-yl]propanoic acid (8).  Methyl 3-[5-chloro-6-
(cyclopropylmethoxy)-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl]propanoate 40a (38 mg, 0.12 
mmol) in dioxane (5 mL) was added hydrochloric acid (0.6 N, 5 mL) and the mixture heated 
at 80 °C for 3 h.  The mixture was poured into water (10 mL), extracted with ethyl acetate (2x 
  
10 mL) and the combined organics dried (sodium sulphate).  The residue was purified by 
preparative HPLC, eluting with an acetonitrile / water gradient containing 0.1 % TFA (40 - 
70 % acetonitrile) to give 3-[5-chloro-6-(cyclopropylmethoxy)-2-oxo-2,3-dihydro-1,3-
benzoxazol-3-yl]propanoic acid as a white solid (12 mg, 54 %).  This material was treated 
with 2-amino-2-(hydroxymethyl)propane-1,3-diol (19 mg, 0.16 mmol) in methanol (5 mL) 
and the mixture stirred at room temperature for 0.5 h.  The solvent was evaporated to give the 
title compound as a white solid (30 mg). 
1
H NMR (CD3OD) 7.39 (s, 1H), 7.09 (s, 1H), 4.06 
(t, J = 6.9Hz, 2H), 3.88 (d, J = 6.6Hz, 2H), 3.66 (s, 6H), 1.29 (m, 1H), 0.63 (m, 2H), 0.40 (m, 
2H).  LCMS:  MH+ 312, retention time 1.51 min (method B).  
 
2‐(Hydroxymethyl)propane‐1,3‐diol; 
3‐[5‐chloro‐6‐(cyclobutylmethoxy)‐2‐oxo‐2,3‐dihydro‐1,3‐benzoxazol‐3‐yl]propanoic acid 
(9).  To methyl 3‐[5‐chloro‐6‐(cyclobutylmethoxy)‐2‐oxo‐2,3‐dihydro‐ 
1,3‐benzoxazol‐3‐yl]propanoate 40b (80 mg, 0.24 mmol) in dioxane (2 mL) was added 
hydrochloric acid (0.5 N, 2 mL) and the reaction stirred at 85 °C for 3h.  Water (5 mL) was 
added and the mixture extracted with ethyl acetate (3x 10 mL).  The combined organic phases 
were dried (sodium sulphate) and purified by preparative HPLC eluting with an acetonitrile / 
water gradient containing 0.1 % TFA (60-70 % acetonitrile) to give a white solid (30 mg).  
This material was dissolved in methanol (5 mL) and treated with 
2‐(hydroxymethyl)propane‐1,3‐diol (10 mg, 0.08mmol).  The mixture was stirred at ambient 
temperature for 30 mi and concentrated to give the title compound as a white solid (40 mg, 38 
%).  
1
H NMR (CD3OD) 7.40 (s, 1H), 7.11 (s, 1H), 4.05 (t, J = 7.0Hz, 2H), 3.98 (d, J = 6.4, 
2H), 3.66 (s, 6H), 2.80 (m, 1H), 2.64 (t, J = 7.0Hz, 2H), 2.14 (m, 2H), 1.99 (m, 4H).  LCMS:  
MH+ 326, retention time 1.57 min (method A).  
 
  
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-[5-chloro-6-(2-methoxyethoxy)-2-oxo-2,3-
dihydro-1,3-benzoxazol-3-yl]propanoic acid (10).  Methyl 3-[5-chloro-6-(2-methoxyethoxy)-
2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl]propanoate 40c (49 mg, 0.15 mmol) was treated with 
hydrochloric acid (0.5 N, 2 mL) in dioxane (4 mL) at 80 °C for 2 h.  The solvent was 
evaporated and the residue purified by column chromatography (silica gel 200-300 mesh, 
petroleum ether / ethyl acetate 2:1, 200 mL).  Evaporation of the solvents gave 3-[5-chloro-6-
(2-methoxyethoxy)-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl]propanoic acid as a white solid 
(20 mg, 43 %).  A sample of this material (10 mg, 0.03 mmol) was treated with 2-amino-2-
(hydroxymethyl)propane-1,3-diol (3.8 mg, 0.03 mmol) in ethanol (3 mL) and water (1 mL) at 
ambient temperature for 1 h.  Removal of the solvents gave the title compound as an off-
white solid (13.8 mg, 100 %).  
1
H NMR (CD3OD) 7.41 (s, 1H), 7.13 (s, 1H), 4.12 (m, 2H), 
4.04 (t, J = 7.2Hz, 2H), 3.76 (m, 2H), 3.59 (s, 6H), 3.44 (s, 3H), 2.57 (t, J = 7.2Hz, 2H).  
LCMS:  MH+ 316/318, retention time 1.40 min (method B).  
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-2-oxo-6-[2-(pyrrolidin-1-
yl)ethoxy]-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid (11).  Methyl 3-{5-chloro-2-oxo-
6-[2-(pyrrolidin-1-yl)ethoxy]-2,3-dihydro-1,3-benzoxazol-3-yl}propanoate  40d (0.1 g, 0.27 
mmol) was treated with hydrochloric acid (0.5 N, 2 mL) in dioxane (2 mL) and the mixture 
stirred at 80 °C for 3 h.  The mixture was concentrated and the residue purified by preparative 
HPLC eluting with an acetonitrile / water gradient containing 0.1 % TFA (10 – 15 % 
acetonitrile), to give 3-{5-chloro-2-oxo-6-[2-(pyrrolidin-1-yl)ethoxy]-2,3-dihydro-1,3-
benzoxazol-3-yl}propanoic acid as a yellow oil (20 mg, 21 %).  This material was treated 
with 2-amino-2-(hydroxymethyl)propane-1,3-diol (10 mg) in methanol (2 mL) and stirred at 
ambient temperature for 0.5 h.  The mixture was concentrated to give the title compound as a 
yellow oil (3 mg, 20 %).  
1
H NMR (CD3OD) 7.45 (s, 1H), 7.17 (s, 1H), 4.27 (t, J = 5.1Hz, 
  
2H), 4.05 (t, J = 6.9Hz, 2H), 3.64 (s, 6H), 3.38 (t, J = 5.1Hz, 2H), 3.20 (m, 4H), 2.58 (t, J = 
7.0Hz, 2H), 2.00 (m, 4H).  LCMS:  MH+ 355, retention time 1.11 min (method A). 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-[6-(benzyloxy)-5-chloro-2-oxo-2,3-dihydro-
1,3-benzoxazol-3-yl]propanoic acid (12).  Methyl 3-[6-(benzyloxy)-5-chloro-2-oxo-2,3-
dihydro-1,3-benzoxazol-3-yl]propanoate 40e (80 mg, 0.22 mmol) was treated with 
hydrochloric acid (0.5 N, 3 mL) in dioxane (5 mL) and the mixture stirred at 80 °C for 2 h.  
The cooled mixture was diluted with water (10 mL) and extracted with ethyl acetate (3x 10 
mL).  The combined organic phases were dried over sodium sulphate and the solvent 
removed.  The residue was purified by preparative HPLC eluting with an acetonitrile / water 
gradient containing 0.1 % TFA (40 – 70 % acetonitrile), to give 3-[6-(benzyloxy)-5-chloro-2-
oxo-2,3-dihydro-1,3-benzoxazol-3-yl]propanoic acid as a white solid (17 mg, 22 %).  This 
material was treated with 2-amino-2-(hydroxymethyl)propane-1,3-diol (6 mg, 0.05 mmol) in 
ethanol (3 mL) and water (1 mL) and stirred at ambient temperature for 0.5 h.  The mixture 
was concentrated to give the title compound as a white solid (23 mg, 100 %).  
1
H NMR 
(CD3OD) 7.48 – 7.30 (m, 6H0, 7.15 (s, 1H), 5.14 (s, 2H), 3.55 (s, 6H), 4.04 (t, J = 7.1Hz, 
2H), 2.57 (t, J = 7.2Hz, 2H).  LCMS:  MH+ 348, retention time 1.55 min (method A). 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-[5-chloro-2-oxo-6-(pyridin-2-ylmethoxy)-
2,3-dihydro-1,3-benzoxazol-3-yl]propanoic acid (13).  Methyl 3-[5-chloro-2-oxo-6-(pyridin-
2-ylmethoxy)-2,3-dihydro-1,3-benzoxazol-3-yl]propanoate 40f (135 mg, 0.37 mmol) was 
treated with hydrochloric acid (0.5 N, 4 mL) in dioxane (8 mL) and the mixture stirred at 80 
°C for 2 h.  The mixture was concentrated and the residue purified by preparative HPLC 
eluting with an acetonitrile / water gradient containing 0.1 % TFA (20 – 60 % acetonitrile), to 
give 3-[5-chloro-2-oxo-6-(pyridin-2-ylmethoxy)-2,3-dihydro-1,3-benzoxazol-3-yl]propanoic 
  
acid as a white solid (35 mg, 27 %).  This material was treated with 2-amino-2-
(hydroxymethyl)propane-1,3-diol (13 mg, 0.1 mmol) in ethanol (3 mL) and water (1 mL) and 
stirred at ambient temperature for 1 h.  The mixture was concentrated to give the title 
compound as a white solid (50 mg, 100 %).  
1
H NMR (CD3OD) 8.65 (d, J = 4.5Hz, 1H), 8.00 
(m, 1H), 7.90 (d, J = 7.9Hz, 1H), 7.53 (s, 1H), 7.49 (m, 1H), 7.33 (s, 1H), 5.32 (s, 2H), 4.17 
(t, J = 6.7Hz, 2H), 3.76 (s, 6H), 2.86 (t, J = 6.7Hz, 2H).   LCMS:  MH+ 349/351, retention 
time 1.34 min (method A). 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-2-oxo-6-[1-(pyridin-2-yl)ethoxy]-
2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid (14) was prepared as described in reference 
19. 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; (R)-3-(5-chloro-2-oxo-6-(1-(pyridin-2-
yl)ethoxy)benzo[d]oxazol-3(2H)-yl)propanoate (15) was prepared as described in reference 
19. 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; (S)-3-(5-chloro-2-oxo-6-(1-(pyridin-2-
yl)ethoxy)benzo[d]oxazol-3(2H)-yl)propanoate (16) was prepared as described in reference 
19. 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-6-[(1R)-1-(1,3-oxazol-2-
yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid (17).  A stirred solution of 
(R)-ethyl 3-(5-chloro-6-(1-(oxazol-2-yl)ethoxy)-2-oxobenzo[d]oxazol-3(2H)-yl)propanoate 
40h (50 mg, 0.13 mmol) in THF (5 mL) and water (1 mL) was cooled to 0 °C and lithium 
hydroxide monohydrate (6 mg, 0.13 mmol) added slowly.  The reaction was maintained at 0 
  
°C for 30 min and then allowed to warm to ambient temperature and maintained at this 
temperature for 2 h.  The THF was evaporated in vacuo and cool water (50 mL) added to the 
residue.  The aqueous phase pH was adjusted to pH 4 by addition of 10 % citric acid solution.  
The mixture was extracted with ethyl acetate (3x 30 mL), the combined organic layers dried 
(sodium sulphate) and concentrated under reduced pressure.  The residue was purified by 
washing with 20% ether in n-pentane (3x 5 mL) to give 3-{5-chloro-6-[(1R)-1-(1,3-oxazol-2-
yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid as a white solid (30 mg, 
65 %).    This material, dissolved in methanol (5 mL) at 20 °C was treated with 2-amino-2-
(hydroxymethyl)propane-1,3-diol (10 mg, 0.085 mmol) and the reaction stirred at this 
temperature for 10 min.  The reaction was allowed to warm to room temperature, then 
warmed slowly to 60 °C and maintained at 60 °C for 2 h.  The reaction was cooled to ambient 
temperature, the solvent evaporated in vacuo and the residue purified by washing with 30% 
ether in n-pentane (3x 5 mL) to give the title compound as an off-white solid (40 mg, 98 %). 
1H NMR (D6-DMSO) includes 8.34 (s, 1H), 8.12 (s, 1H), 7.49 (s, 1H), 7.39 (s, 1H), 5.49 (q, 
J = 6.5Hz, 1H), 3.92 (t, J = 7.0, 2H), 3.34 (s, 6H), ~2.50 (m, partially obscured by DMSO), 
1.60 (d, J = 6.4Hz, 3H).  LCMS:  [M-H]
-
 351, retention time 1.81 min (method D). 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-2-oxo-6-[(1R)-1-(pyrimidin-2-
yl)ethoxy]-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid (18).  A stirred solution of (R)-
ethyl 3-(5-chloro-2-oxo-6-(1-(pyrimidin-2-yl)ethoxy)benzo[d]oxazol-3(2H)-yl)propanoate 
40i (200 mg, 0.51 mmol) in THF (5 mL) and water (1 mL) was cooled to 0 °C and lithium 
hydroxide monohydrate (42 mg, 1.02 mmol) added slowly.  The reaction was maintained at 0 
°C for 30 min and then allowed to warm to ambient temperature and maintained at this 
temperature for 2 h.  The THF was evaporated and water (50 mL) added to the residue.  The 
aqueous phase pH was adjusted to pH 4 by addition of 10 % citric acid solution.  The mixture 
  
was extracted with ethyl acetate (3x 30 mL), the combined organic layers dried (sodium 
sulphate) and concentrated under reduced pressure.  The residue was purified by preparative 
HPLC (column: Sunfire 250x 30 mm, 10 µ, eluent: 0.1% formic acid in aqueous acetonitrile, 
flow rate: 30 mL / min) to give 3-{5-chloro-2-oxo-6-[(1R)-1-(pyrimidin-2-yl)ethoxy]-2,3-
dihydro-1,3-benzoxazol-3-yl}propanoic acid as an off white solid (90 mg, 48 %).  This 
material, dissolved in methanol (10 mL) at 20 °C was treated with 2-amino-2-
(hydroxymethyl)propane-1,3-diol (30 mg, 0.247 mmol) and the reaction stirred at 20-25 °C 
for 10 min.  The reaction was allowed to warm to room temperature and then maintained at 
60 °C for 2 h.  The solvent was evaporated in vacuo and the residue purified by washing with 
n-pentane (3x 5 mL) to give the title compound as an off-white solid (80 mg, 70 %). 1H 
NMR (D6-DMSO) 8.83 (d, J = 5.0Hz, 2H), 7.49 (s, 1H), 7.45 (t, J = 4.9Hz, 1H), 7.08 (s, 1H), 
3.54 (q, J = 6.4, 1H), 3.91 (t, J = 7.0Hz, 2H), 3.33 (s, 6H), 1.68 (d, 3H).  LCMS:  MH+ 364, 
retention time 255 min (method E). 
 
3-{5-Chloro-2-oxo-6-[(1R)-1-(pyridazin-3-yl)ethoxy]-2,3-dihydro-1,3-benzoxazol-3-
yl}propanoic acid (19).  Methyl 3-{5-chloro-2-oxo-6-[1-(pyridazin-3-yl)ethoxy]-2,3-dihydro-
1,3-benzoxazol-3-yl}propanoate 40j (380 mg, ~60% purity) was treated with hydrochloric 
acid (0.5 N, 10 mL) in dioxane (10 mL) and the mixture stirred at 90 °C for 5 h.  The mixture 
was concentrated and the residue purified by preparative HPLC eluting with an acetonitrile / 
water gradient containing 0.1 % TFA (20 – 50 % acetonitrile, Gemini-C18 column 
(150*21.2mm, 5μm)), to give 3-{5-chloro-2-oxo-6-[1-(pyridazin-3-yl)ethoxy]-2,3-dihydro-
1,3-benzoxazol-3-yl}propanoic acid as a white solid (120 mg).  The racemic mixture was 
separated by chiral chromatography (chiral column-IC, mobile phase: 30% Hexane:70% 
EtOH + 0.2%DEA-FA, flow rate-0.8 mL/min) to give 3-{5-chloro-2-oxo-6-[(1S)-1-
(pyridazin-3-yl)ethoxy]-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid (54 mg, 25 %, 
  
chiral retention time 27.44 min) and the title compound as a white solid (58 mg, 26 %, chiral 
retention time 13.72 min).  
1
H NMR (CD3OD) 9.12 (d, J = 4.4Hz, 1H), 7.95 (d, J = 8.5Hz, 
1H), 7.76 (dd, J = 8.5Hz, J = 5.6Hz, 1H), 7.39 (s, 1H), 7.11 (s, 1H), 5.77 (q, J = 5.9, 1H), 4.05 
(t, J = 6.2Hz, 2H), 2.76 (t, J = 5.9Hz, 3H), 1.77 (d, J = 6.5Hz, 3H).  LCMS:  MH+ 364/366, 
retention time 1.37 min (method A).   
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-6-[(1R)-1-(4-methylpyridin-2-
yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid (20).  Methyl 3-{5-chloro-
6-[(1R)-1-(4-methylpyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoate 
40k (130 mg, 0.33 mmol) in hydrochloric acid (6 N, 5 mL) was heated at 100 °C for 2 h.  The 
mixture was concentrated and the residue purified by preparative HPLC eluting with an 
acetonitrile / water gradient containing 0.1 % TFA (30 – 60 % acetonitrile, Gemini-C18 
column (150*21.2mm, 5μm)), to give 3-{5-chloro-6-[(1R)-1-(4-methylpyridin-2-yl)ethoxy]-
2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid as a yellow solid (25 mg, 20 %).  
This material was treated with 2-amino-2-(hydroxymethyl)propane-1,3-diol (8 mg, 0.06 
mmol) in methanol (3 mL) and stirred at ambient temperature for 1 h.  The mixture was 
concentrated to give the title compound as a yellow solid (33 mg, 100 %).  
1
H NMR (D6-
DMSO) 8.38 (d, J = 4.8Hz, 1H), 7.49 (s, 1H), 7.33 (s, 1H), 7.17 (s, 1H), 7.12 (d, J = 4.6Hz, 
1H), 5.48 (q, J = 6.4Hz, 1H), 3.90 (t, J= 6.3Hz, 2H), 3.43 (s, 6H), 2.46 (m, partially obscured 
by DMSO), 2.30 (s, 3H), 1.58 (d, J = 6.3Hz, 3H).  LCMS:  MH+ 377, retention time 1.33 min 
(method A).   
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-6-[(1R)-1-(5-methylpyridin-2-
yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid (21).  Methyl 3-{5-chloro-
6-[(1R)-1-(5-methylpyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoate 
  
40l (125 mg) in hydrochloric acid (6 N, 10 mL) was heated at 100 °C for 4 h.  The mixture 
was concentrated and the residue purified by preparative HPLC eluting with an acetonitrile / 
water gradient containing 0.1 % TFA (30 – 60 % acetonitrile, Gemini-C18 column 
(150*21.2mm, 5μm)), to give 3-{5-chloro-6-[(1R)-1-(5-methylpyridin-2-yl)ethoxy]-2-oxo-
2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid as a yellow oil (27 mg, 23 %).  This 
material was treated with 2-amino-2-(hydroxymethyl)propane-1,3-diol (9 mg, 0.07 mmol) in 
methanol (5 mL) and stirred at ambient temperature for 1 h.  The mixture was concentrated to 
give the title compound as a yellow solid (37 mg, 100 %).  
1
H NMR (CD3OD) 8.46 (br s, 
1H), 8.35 (m, 1H), 7.65 (dd, J= 8.1Hz, J = 1.8Hz, 1H), 7.45 (d, J = 7.9Hz, 1H), 7.39 (s, 1H), 
6.90 (s, 1H), 5.40 (q, J = 6.5Hz, 1H), 4.03 (t, J = 6.6Hz, 2H), 3.67 (s, 6H), 2.65 (t, J = 6.6Hz, 
2H), 2.34 (s, 3H), 1.67 (d, J = 6.3Hz, 3H).  LCMS:  MH+ 377, retention time 1.49 min 
(method A). 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-6-[(1R)-1-(5-chloropyridin-2-
yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid (22).  Methyl 3-{5-chloro-
6-[1-(5-chloropyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoate 40m 
(210 mg, 0.5 mmol) in hydrochloric acid (6 N, 8 mL) was heated at 100 °C for 2 h.  The 
mixture was concentrated and the residue purified by preparative HPLC eluting with an 
acetonitrile / water gradient containing 0.1 % TFA (30 – 70 % acetonitrile, Gemini-C18 
column (150*21.2mm, 5μm)).  The resulting yellow oil (130 mg) was further purified by 
chiral HPLC (column: AD-H) to give 3-{5-chloro-6-[(1R)-1-(5-chloropyridin-2-yl)ethoxy]-2-
oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid as a yellow oil (54 mg, 27 %).  This 
material was treated with 2-amino-2-(hydroxymethyl)propane-1,3-diol (16 mg, 0.13 mmol) in 
methanol (5 mL) and stirred at ambient temperature for 1 h.  The mixture was concentrated to 
give the title compound as a yellow oil (70 mg, 100 %).  
1
H NMR (CD3OD) 8.47 (d, J = 
  
2.3Hz, 1H), 7.80 (dd, J = 8.6Hz, J = 2.3Hz, 1H), 7.52 (d, J = 8.3Hz, 1H), 7.37 (s, 1H), 6.91 (s, 
1H), 5.41 (q, J = 6.5Hz, 1H), 3.98 (t, J = 7.1Hz, 2H), 3.62 (s, 6H), 2.53 (t, J = 7.1Hz, 2H), 
1.63 (d, J= 6.3Hz, 3H).  LCMS:  MH+ 397, retention time 1.54 min (method A). 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-6-[(1R)-1-(5-fluoropyridin-2-
yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid (23).  Methyl 3-{5-chloro-
6-[(1R)-1-(5-fluoropyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoate 
40n (120 mg, 0.30 mmol) in hydrochloric acid (6 N, 10 mL) was heated at 70 °C for 4 h.  The 
volatiles were evaporated in vacuo and the residue purified by preparative HPLC eluting with 
an acetonitrile  / water gradient containing 0.1 % TFA (30 – 60 % acetonitrile, Gemini-C18 
column (150*21.2mm, 5μm)), then further purified by preparative chiral HPLC (Chiralpak 
AD-H colmn (250*20 mm, 5μm), mobile phase was: EtOH (Formic Acid):Hexane = 50:50, 
flow rate = 0.8 mL/min, retention time = 7.979min) to give 3-{5-chloro-6-[(1R)-1-(5-
fluoropyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid as a 
yellow oil  (37 mg, 32 %).  This material was treated with 2-amino-2-
(hydroxymethyl)propane-1,3-diol (12 mg, 0.09 mmol) in methanol (5 mL) and stirred at 
ambient temperature for 2 h.  The mixture was concentrated to give the title compound as a 
yellow solid (49 mg, 100 %).  
1
H NMR (CD3OD) 8.42 (s, 1H), 7.61 (d, J = 1.7Hz, 1H), 7.59 
(m, 1H), 7.41 (s, 1H), 6.95 (s, 1H), 5.46 (q, J = 6.6Hz, 1H), 4.02 (t, J = 7.3Hz, 2H), 3.65 (s, 
6H), 2.57 (t, J = 7.1Hz, 2H), 1.67 (d, J = 6.6Hz, 3H).  LCMS:  MH+ 381, retention time 1.45 
min (method A). 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-6-[(1R)-1-(6-methylpyridin-2-
yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoic acid (24).  Methyl 3-{5-chloro-
6-[(1R)-1-(6-methylpyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl}propanoate 
  
40o (110 mg, 0.28 mmol) in hydrochloric acid (6 N, 10 mL) was heated at 100 °C for 2 h.  
The solvent was evaporated in vacuo and the residue purified by preparative HPLC eluting 
with an acetonitrile  / water gradient containing 0.1 % TFA (40 – 60 % acetonitrile, Gemini-
C18 column (150*21.2mm, 5μm)), then further purified by preparative chiral HPLC (AD-H, 
formic acid) to give 3-{5-chloro-6-[(1R)-1-(6-methylpyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-
1,3-benzoxazol-3-yl}propanoic acid as a yellow solid (14 mg, 13 %).  This material was 
treated with 2-amino-2-(hydroxymethyl)propane-1,3-diol (4 mg, 0.03 mmol) in methanol (5 
mL) and stirred at ambient temperature for 1 h.  The mixture was concentrated to give the 
title compound as a white solid (17 mg, 100 %).  
1
H NMR (CD3OD) 8.64 (br. S, 1H), 7.68 (t, 
J = 7.6Hz, 1H), 7.39 (s, 1H), 7.34 (d, J = 7.9Hz, 1H), 7.18 (d, J = 7.6Hz, 1H), 6.89 (s, 1H), 
5.38 (q, J = 6.4Hz, 1H), 4.02 (t, J = 6.8Hz, 2H), 3.67 (s, 6H), 2.65 (t, J = 6.8Hz, 2H), 2.55 (s, 
3H), 1.67 (d, J = 6.6Hz, 3H).  LCMS:  MH+ 377, retention time 1.35 min (method A). 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{6-chloro-3-oxo-7-[(1R)-1-(pyridin-2-
yl)ethoxy]-3,4-dihydro-2H-1,4-benzoxazin-4-yl}propanoic acid (25).  To methyl 3-{6-chloro-
3-oxo-7-[(1R)-1-(pyridin-2-yl)ethoxy]-3,4-dihydro-2H-1,4-benzoxazin-4-yl}propanoate 47 
(0.28 g 0.41 mmol) in dioxane (5 mL) was added hydrochloric acid (0.5 N, 5 mL) and the 
mixture stirred at 80 °C for 16 h.   The solvent was removed and the residue purified by 
preparative HPLC eluting with an acetonitrile / water gradient containing 0.1 % TFA (20 – 30 
% acetonitrile).  Further purification was attempted by SFC (c. hexane/ethanol 1:1, 0.2% 
formic acid, and diethylamine on chiralpak-AD).  The material was further purified by 
preparative HPLC eluting with an acetonitrile  / water gradient containing 0.1 % TFA (20 – 
40 % acetonitrile) to give 3-{6-chloro-3-oxo-7-[(1R)-1-(pyridin-2-yl)ethoxy]-3,4-dihydro-
2H-1,4-benzoxazin-4-yl}propanoic acid as a white solid (50 mg, 32 %).  This material was 
treated with 2-amino-2-(hydroxymethyl)propane-1,3-diol (15 mg, 0.03 mmol) in methanol (2 
  
mL) and stirred at ambient temperature for 0.5 h.  The mixture was concentrated to give the 
title compound as a white solid (65 mg, 100 %).  
1
H NMR (CD3OD) 8.51 (m, 1H), 7.83 (m, 
1H), 7.54 (d, J = 7.9Hz, 1H), 7.33 (ddd, J= 7.6Hz, J = 5.0Hz, J = 1.3Hz, 1H), 7.28 (s, 1H), 
6.57 (s, 1H0, 5.41 (q, J = 6.6Hz, 1H), 4.51 (d, J = 2.3Hz, 2H), 4.15 (t, J = 7.6Hz, 2H), 3.65 (s, 
6H), 2.59 (t, J = 7.6Hz, 2H), 1.67 (d, J= 6.3Hz, 3H).  LCMS:  MH+ 377, retention time 1.37 
min (method A). 
 
3-{6-Chloro-5-[(1R)-1-(pyridin-2-yl)ethoxy]-1H-indol-1-yl}propanoic acid (26).  3-(6-
chloro-5-hydroxy-1H-indol-1-yl)propanoate 50 (112 mg, 0.42 mmol) and (1S)-1-(pyridin-2-
yl)ethan-1-ol (57 mg, 0.46 mmol), triphenyl phosphine (132 mg, 0.50 mmol) and DEAD (88 
mg, 0.50 mmol) were mixed in toluene (5 mL) and the reaction stirred at ambient temperature 
for 16 h.  The solvent was removed by evaporation and the residue   ethyl 3-{6-chloro-5-
[(1R)-1-(pyridin-2-yl)ethoxy]-1H-indol-1-yl}propanoate 51 (390 mg, crude) used directly in 
the next reaction.   To this material was added aqueous lithium hydroxide (0.5 N, 10mL) and 
THF (8mL) and the mixture stirred at ambient temperature for 2h.  Water (20 mL) was added 
and the mixture washed with ethyl acetate (3x 10 mL).  The aqueous was acidified (pH 4 -5) 
with hydrochloric acid (0.5N) and extracted with ethyl acetate (4x 10 mL).  The combined 
organics were reduced to dryness and the residue purified by preparative HPLC eluting with 
an acetonitrile / water gradient containing 0.1 % TFA (30 – 70 % acetonitrile, Gemini-C18 
column (150*21.2mm, 5μm)) to give the title compound as a white solid (26 mg, 18%).  1H 
NMR (CD3OD) 8.49 (m, 1H), 7.80 (td, J = 7.6Hz, J = 7.6Hz, J = 1.8Hz, 1H), 7.60 (d, J = 
7.9Hz, 1H), 7.49 (s, 1H), 7.29 (ddd, J = 7.6Hz, J = 5.0Hz, J = 1.2Hz, 1H), 7.15 (d, J = 3.2Hz, 
1H), 6.96 (s, 1H), 6.22 (dd, J = 3.1Hz, J = 0.7Hz, 1H), 5.41 (q, J = 6.3Hz, 1H), 4.36 (t, J = 
6.6Hz, 2H), 2.74 (t, J = 6.6Hz, 2H), 1.68 (d, J = 6.5Hz, 3H).  (LCMS:  MH+ 345 / 347, 
retention time 1.42 min (method A). 
  
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{6-chloro-5-[(1R)-1-(pyridin-2-yl)ethoxy]-
1H-indazol-1-yl}propanoic acid (27).  Ethyl 3-{6-chloro-5-[(1R)-1-(pyridin-2-yl)ethoxy]-1H-
indazol-1-yl}propanoate 56 (0.1 g, 0.27 mmol) in THF (5 mL) was added lithium hydroxide 
(1 N, 0.5 mL) and the reaction stirred at ambient temperature for 16 h.  The solvents were 
evaporated and the residue diluted with water (5 mL).  The mixture was acidified (< pH 7) 
with hydrochloric acid (1 N) and the mixture extracted with ethyl acetate (2x 10 mL).  The 
combined organic extracts were dried (sodium sulphate) and purified by preparative HPLC 
eluting with an acetonitrile / water gradient containing 0.1 % TFA (20 – 50 % acetonitrile, 
Gemini-C18 column (150*21.2mm, 5μm)) to give 3-{6-chloro-5-[(1R)-1-(pyridin-2-
yl)ethoxy]-1H-indazol-1-yl}propanoic acid (45 mg, 43 %) as a yellow oil.  This material was 
treated with 2-amino-2-(hydroxymethyl)propane-1,3-diol (16 mg, 0.13 mmol) in methanol (2 
mL) and the mixture stirred at ambient temperature for 30 min.  The mixture was 
concentrated to give the title compound as a white solid (60 mg, 100%).  
1
H NMR (CD3OD)  
8.52 (m, 1H), 7.80 (m, 3H), 7.57 (d, J=7.9Hz, 1H), 7.32 (ddd, J = 7.6Hz, J = 5.0Hz, J = 
1.0Hz, 1H), 7.07 (s, 1H), 5.47 (q, J = 6.3Hz, 1H), 4.56 (t, J = 7.1Hz, 2H), 3.66 (s, 6H), 2.72 
(t, J = 7.1Hz, 2H), 1.71 (d, J = 6.6Hz, 3H).  LCMS:  MH+ 346, retention time 1.44 min 
(method A). 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-6-[(1R)-1-(pyridin-2-yl)ethoxy]-
1,2-benzoxazol-3-yl}propanoic acid (28) was prepared as described in reference 20. 
 
3-{5-Chloro-2-oxo-6-[(1R)-1-(pyridin-2-yl)ethoxy]-2,3-dihydro-1,3-benzothiazol-3-
yl}propanoic acid (29).  Ethyl 3-(5-chloro-6-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-3-
yl)propanoate 68 (106 mg, 0.35 mmol), (1S)-1-(pyridin-2-yl)ethan-1-ol (48 mg, 0.39 mmol), 
  
triphenyl phosphine (120 mg, 0.45 mmol) and DEAD (92 mg, 0.53 mmol) were mixed in 
toluene (5 mL) and the mixture stirred at ambient temperature for 16 h.  The solvent was 
evaporated and the residue purified by column chromatography (silica gel, 200-300 mesh, 4 
g) eluting with petroleum ether / ethyl acetate (4:1). To give ethyl 3-{5-chloro-2-oxo-6-[(1R)-
1-(pyridin-2-yl)ethoxy]-2,3-dihydro-1,3-benzothiazol-3-yl}propanoate 69 as a yellow oil 
(212 mg, crude).  This material was treated with hydrochloric acid (0.5 N, 3 mL) in dioxane 
(3 mL) at 90 °C for 3 h.  The reaction was concentrated and the residue purified by 
preparative HPLC eluting with an acetonitrile / water gradient containing 0.1 % TFA (40 – 60 
% acetonitrile, Gemini-C18 column (150*21.2mm, 5μm)) to give the title compound as an 
off-white solid (59 mg, 44 %).  
1
H NMR (CD3OD) 8.67 (d, J = 4.7Hz, 1H), 8.22 (t, J = 7.2Hz, 
1H), 7.87 (d, J = 7.9Hz, 1H), 7.67 (m, 1H), 7.48 (s, 1H), 7.27 (s, 1H), 5.61 (q, J = 6.5Hz, 1H), 
4.17 (t, J = 6.9Hz, 2H), 2.70 (t, J = 6.9Hz, 2H), 1.76 (d, J = 6.5Hz, 3H).  LCMS:  MH+ 379 / 
381, retention time 1.46 min (method A). 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-6-[(1R)-1-(5-methylpyridin-2-
yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid (30).  To a stirred suspension of (R)-ethyl 3-
(5-chloro-6-(1-(5-methylpyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate 64b (120 mg, 
0.31 mmol) in THF / water (1:1, 3 mL) at 0 °C, lithium hydroxide (25.8 mg, 0.62 mmol) was 
added portion-wise and the reaction stirred at ambient temperature for 2 h.  The volatiles 
were evaporated and the residue diluted with water. The mixture was washed with diethyl 
ether, the aqueous phase cooled to 0 °C and acidified to pH 4 by addition of 2N hydrochloric 
acid.  The mixture was extracted with 10 % methanol in DCM, the organic washed with 
water and dried (sodium sulphate).  The solvent was evaporated to give 3-{5-chloro-6-[(1R)-
1-(5-methylpyridin-2-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid as an off white solid 
(90 mg, 81 %).  This material was suspended in methanol (5 mL), 2-amino-2-
  
(hydroxymethyl)propane-1,3-diol (27.3 mg) added to the mixture and the reaction heated at 
reflux for 3 h.  The volatiles were evaporated in vacuo and the residue co-distilled with DCM.  
The white solid was washed with n-pentane and dried to give the title compound as an off-
white solid (75mg, 63%).  
1
H NMR (D6-DMSO) 8.41 (s, 1H), 8.03 (s, 1H), 7.62 (d, J = 
7.9Hz, 1H), 7.38 (d, J = 7.9Hz, 1H), 7.32 (s, 1H), 5.71 (q, J = 6.4Hz, 1H), 3.08 (t, J = 7.1Hz, 
2H), 2.60 (t, J = 7.3Hz, 2H), 2.27 (s, 3H), 1.66 (d, J = 6.4Hz, 3H).  LCMS:  MH+ 361, 
retention time 2.08 min (method D).   
 
3-{5-chloro-6-[(1R)-1-(5-methylpyridin-2-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid  
hydrochloride salt (30a).  3-{5-chloro-6-[(1R)-1-(5-methylpyridin-2-yl)ethoxy]-1,2-
benzoxazol-3-yl}propanoic acid (39 g, 108 mmol) in hydrochloric acid (0.5 N, 500 mL) was 
stirred at ambient temperature for 16 h.  The solid was isolated by filtration and dried.  The 
solid was dissolved in DCM (600 mL) and methanol(100 mL) and n-hexane (2 L) was added 
dropwise.  The resulting solid was isolated by filtration to give the title compound as a white 
solid (35 g, 18 %).  
1
H NMR (CD3OD) 8.75 (s, 1H), 8.51 (dd, J = 8.3, 1.4 Hz, 1H), 8.13 (d, J 
= 8.3 Hz, 1H), 7.99 (s, 1H), 7.39 (s, 1H), 6.01 (q, J = 6.5 Hz, 1H), 3.25 (q, J = 7.4 Hz, 2H), 
2.86 (t, J = 7.2 Hz, 2H), 2.59 (s, 3H), 1.89 (d, J = 6.5 Hz, 3H) LCMS:  MH+ 361, retention 
time 1.48 min (method A). 
 
2-Amino-2-(hydroxymethyl)propane-1,3-diol; 3-{5-chloro-6-[(1R)-1-(5-chloropyridin-2-
yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid  (31).  To a stirred suspension of (R)-ethyl 3-
(5-chloro-6-(1-(5-chloropyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate 64c (140 mg, 
0.34 mmol) in THF  (5 mL) and  water (2 mL), lithium hydroxide.monohydrate (43 mg, 1.02 
mmol) was added and the reaction stirred at ambient temperature for 3 h.  The reaction was 
concentrated to removed the THF and the aqueous acidified to pH 2 with 2N hydrochloric 
  
acid.  The mixture was extracted with 10 % methanol in DCM, the organic dried (sodium 
sulphate) and the solvent was evaporated.  The residue was triturated with pentane to give 3-
{5-chloro-6-[(1R)-1-(5-chloropyridin-2-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid as an 
off white solid (105 mg, 80 %).  100mg of this material was dissolved in methanol (5 mL), 2-
amino-2-(hydroxymethyl)propane-1,3-diol (30.2  mg, 0.25 mmol) added to the mixture and 
the reaction heated at 70 °C for 3 h.  The volatiles were evaporated in vacuo and the residue 
triturated with pentane to give the title compound as an off-white solid (85mg, 65%).  
1
H 
NMR (D6-DMSO) 8.64 (d, J = 2.0Hz, 1H), 8.06 (s, 1H), 7.96 (dd, J = 8..4Hz, J = 2.5Hz, 1H), 
7.56 (d, J = 8.3Hz, 1H), 7.40 (s, 1H), 5.80 (q, J = 6.4Hz, 1H), 3.31 (s, 6H), 3.10 (t, J = 7.3Hz, 
2H), 2.63 (t, J = 7.3Hz, 2H), 1.67 (d, J = 6.4Hz, 3H).  LCMS:  MH+ 381, retention time 2.44 
min (method D). 
 
3-{5-Chloro-6-[(1R)-1-(5-fluoropyridin-2-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid 
(32).  To a stirred suspension of (R)-methyl 3-(5-chloro-6-(1-(5-fluoropyridin-2-
yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate 64d (150 mg, 0.40 mmol) in THF  (10 mL) was 
added lithium hydroxide solution (0.5 N, 3.2 mL) and the reaction stirred at ambient 
temperature for 2 h.  The reaction was concentrated, the residue diluted with water (10 mL) 
and acidified to pH 3 - 4 with 0.5N hydrochloric acid.  The mixture was extracted with ethyl 
acetate (4x 10 mL).  The combined organic extracts were dried (sodium sulphate) and 
concentrated to give the title compound as an off-white solid (65mg, 45%).  NMR (CD3OD) 
8.49 (s, 1H), 7.89 (s, 1H), 7.72 – 7.56 (m, 2H), 7.14 (s, 1H), 5.68 (q, J = 6.4Hz, 1H), 3.21 (t, J 
= 7.3Hz, 2H), 2.84 (t, J = 7.3Hz, 2H), 1.76 (d, J = 6.4Hz, 3H).  LCMS:  MH+ 365, retention 
time 1.50 min (method A). 
 
  
3-{5-chloro-6-[(1R)-1-(6-methylpyridazin-3-yl)ethoxy]-1,2-benzoxazol-3-yl}propanoic acid 
(33) was prepared as described in reference 20. 
 
Amino-4-chloro-5-isobutylphenol (34d).  A mixture of 4-chloro-5-isobutyl-2-nitrophenol 77 
(420 mg, 1.83 mmol), zinc (600 mg, 9.17 mmol) and acetic acid (1 mL) in ethanol (20 mL) 
was heated at 85 °C for 1 h.  The mixture was filtered and the solvents removed in vacuo.  
The title compound as the residual yellow solid was used without further purification (420 
mg).  LCMS:  MH+ 200, retention time 1.55 min (method A). 
 
2-Amino-4-chloro-5-ethoxyphenol (34f).  4-Chloro-5-ethoxy-2-nitrophenol
21 
(700 mg, 3.22 
mmol) in ethanol (20 mL) and acetic acid (2 mL) was treated with zinc (2 g, 32.2 mmol) and 
stirred at 60 °C for 1 h.  The reaction was filtered and the filtrate reduced to dryness in vacuo 
to give the crude title as a yellow solid, which was used without further purification (600 
mg).  LCMS:  MH+ 188, retention time 1.21 min (method A). 
 
2-Amino-4-chloro-5-cyclopropoxyphenol (34g).  5-Chloro-4-cyclopropoxy-2-methoxyaniline 
81 (470 mg, 2.21 mmol) was dissolved in DCM (10 mL) at 0 °C.  Boron tribromide (1.1 g, 
4.42 mmol) was added slowly and the reaction stirred for 1 h at ambient temperature 
following completion of the addition.  The solvent was evaporated in vacuo and water 
(30mL) added slowly to the residue.  The pH was adjusted to ~pH 8 with saturated sodium 
hydrogen carbonate and the mixture extracted with ethyl acetate (4x 20 mL).  The combined 
organic phases were dried (sodium sulphate) and reduced to dryness in vacuo to give the 
crude title compound as a black oil (360 mg, 82 %).  LCMS:  MH+ 200 / 202, retention time 
1.20 min (method A). 
 
  
5-Chloro-6-ethyl-2,3-dihydro-1,3-benzoxazol-2-one (35c).  2-Amino-4-chloro-5-ethylphenol 
34c
22
 (360 mg, 2.1 mmol) in THF (15 mL) was treated with CDI (683 mg, 4.2 mmol) and the 
mixture stirred at 60 °C for 1 h.  The solvent was evaporated and the residue purified by 
chromatography (silica gel, 200-300 mesh, 10 g) eluting with petroleum ether : ethyl acetate 
(4:1) to give the title compound as a brown solid (47 mg, 100 %).  LCMS:  MH+ 196 / 198, 
retention time 1.38 min (method B). 
 
5-Chloro-6-(2-methylpropyl)-2,3-dihydro-1,3-benzoxazol-2-one  (35d).  2-Amino-4-chloro-5-
isobutylphenol 34d (400 mg, 2.0 mmol) in THF (20 mL) was treated with CDI (648 mg, 4.0 
mmol) and the mixture heated at 80 °C for 2 h.  The solvent was evaporated in vacuo and the 
residue purified by chromatography (silica gel), eluting with petroleum ether  / ethyl acetate 
(20:1) to give the title compound as a yellow oil (240 mg, 54 %).  LCMS:  MH+ 226, 
retention time 1.61 min (method A). 
 
5‐Chloro‐6‐methoxy‐2,3‐dihydro‐1,3‐benzoxazol‐2‐one (35e).  2-Amino-4-chloro-5-
methoxyphenol
23
 34e (435 mg, 2.57 mmol) in DCM (20 mL) were added triethylamine (635 
mg, 6.28 mmol) and triphosgene (260 mg, 0.88 mmol) at 0 °C and the mixture stirred at 0 °C 
for 2 h.   The solvent was evaporated and the residue purified by chromatography (silica gel, 
200-300 mesh, 4 g) eluting with petroleum ether / ethyl acetate (4:1) to give the title 
compound as a yellow solid (0.3 g, 60 %).  
1
H NMR (D6-DMSO) 11.57 (br. s, 1H), 7.30 (s, 
1H), 7.16 (s, 1H), 3.82 (s, 3H). 
 
5‐Chloro‐6‐ethoxy‐2,3‐dihydro‐1,3‐benzoxazol‐2‐one (35f).  2-Amino-4-chloro-5-
ethoxyphenol 34f (700 mg, 3.74 mmol) in DCM (20 mL) at ambient temperature was treated 
with triethylamine (1 mL) and then with triphosgene (1.1 g, 3.74 mmol).  The reaction was 
  
stirred for 4 h.  The solvent was evaporated in vacuo and the residue purified by 
chromatography (silica gel) eluting with petroleum ether / ethyl acetate (9:1, 5:1 then 4:1) to 
give the title compound as a pink solid (380 mg, 44 %).  
1
H NMR (CD3OD) 7.09 (s, 1H), 
7.08 (s, 1H), 4.08 (q, J = 6.9Hz, 2H), 1.42 (t, J = 6.9Hz, 3H). 
 
5-Chloro-6-cyclopropoxy-2,3-dihydro-1,3-benzoxazol-2-one (35g).  A mixture of 2-amino-4-
chloro-5-cyclopropoxyphenol 34g (300 mg, 1.89 mmol), CDI (587 mg, 3.62 mmol) in THF 
(20 mL) was stirred at 60 °C for 1 h.  A second mixture of 4-chloro-5-cyclopropoxy-2-
nitrophenol 34g (22 mg, 0.11 mmol), CDI (25.3 mg, 0.22 mmol) in THF (5 mL) was stirred 
at 60 °C for 2 h. The solvents were removed from both reactions, the residues combined and 
purified by chromatography (silica gel, 200-300 mesh) eluting with petroleum ether / ethyl 
acetate (30:1) to give the title compound as a brown solid (220 mg, 51 %).  LCMS:  MH+ 
224 / 226, retention time 1.47 min (method B). 
 
Methyl 3-[5-chloro-6-(cyclopropylmethoxy)-2-oxo-2,3-dihydro-1,3-benzoxazol-3-
yl]propanoate (40a).  To methyl 3-(5-chloro-6-hydroxy-2-oxobenzo[d]oxazol-3(2H)-
yl)propanoate
19
 39 (70 mg, 0.26 mmol) in toluene (10 mL) were added cyclopropylmethanol 
(22 mg, 0.31 mmol), DEAD (45 mg, 0.26 mmol) and triphenylphosphine (68 mg, 0.26 mmol) 
and the mixture stirred at ambient temperature for 1.5 h.  Water (10 mL) was added and the 
mixture extracted with ethyl acetate (2x 10 mL).  The combined organics were dried (sodium 
sulphate) and purified by chromatography (silica gel, 200-300 mesh, 2 g), eluting with 
petroleum ether / ethyl acetate (10:1) to give the title compound as a purple solid (38 mg, 45 
%).  LCMS:  MH+ 326, retention time 1.63 min (method A).  
 
  
Methyl 3‐[5‐chloro‐6‐(cyclobutylmethoxy)‐2‐oxo‐2,3‐dihydro‐1,3‐benzoxazol‐3‐yl] 
propanoate (40b).  Methyl 3-(5-chloro-6-hydroxy-2-oxobenzo[d]oxazol-3(2H)-yl)propanoate 
39 (130 mg, 0.48 mmol) in DMF (5 mL) was treated with cyclobutylmethyl 4-
methylbenzenesulfonate (140 mg, 0.57 mmol) and potassium carbonate (130 mg, 0.96 mmol) 
and the mixture stirred at 80 °C for 2 h.  The mixture was poured into water (20 mL), 
extracted with ethyl acetate (3x 10 mL) and the combined organics dried (sodium sulphate).  
The residue was purified by chromatography (silica gel, 200-300 mesh, 10 g) eluting with 
petroleum ether / ethyl acetate (10:1 to 4:1) to give the title compound as a colourless oil (180 
mg, 49 %).  LCMS:  MH+ 340, retention time 1.73 min (method A). 
 
Methyl 3-[5-chloro-6-(2-methoxyethoxy)-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl]propanoate 
(40c).  Methyl 3-(5-chloro-6-hydroxy-2-oxobenzo[d]oxazol-3(2H)-yl)propanoate 39 (100 
mg, 0.37 mmol), 1-bromo-2-methoxyethane (62 mg, 0.44 mmol) and cesium carbonate (180 
mg, 0.55 mmol) were mixed in acetone (5 mL) and stirred at 70 °C for 15 h.  The solvent was 
evaporated and the residue purified by chromatography (silica gel, 200-300 mesh, 10 g) 
eluting with petroleum ether / ethyl acetate (3:1, 150 mL) to give the title compound (49 mg, 
40 %).  LCMS:  MH+ 330/332, retention time 1.51 min (method A). 
 
Methyl 3-{5-chloro-2-oxo-6-[2-(pyrrolidin-1-yl)ethoxy]-2,3-dihydro-1,3-benzoxazol-3-
yl}propanoate  (40d).  To methyl 3-(5-chloro-6-hydroxy-2-oxobenzo[d]oxazol-3(2H)-
yl)propanoate 39 (130 mg, 0.48 mmol) in toluene (10 mL) were added 2-(pyrrolidin-1-
yl)ethanol (66 mg, 0.57 mmol), DEAD (84 mg, 0.48 mmol) and triphenylphosphine (126 mg, 
0.48 mmol) and the mixture stirred at ambient temperature for 48 h.  Water (40 mL) was 
added and the mixture extracted with ethyl acetate (2x 20 mL).  The combined organics were 
dried (sodium sulphate) and purified by chromatography (silica gel, 200-300 mesh, 10 g), 
  
eluting with petroleum ether / ethyl acetate (4:1) to give the title compound as a yellow oil 
(101 mg, 56 %).  LCMS:  MH+ 369, retention time 1.18 min (method A).  
 
Methyl 3-[6-(benzyloxy)-5-chloro-2-oxo-2,3-dihydro-1,3-benzoxazol-3-yl]propanoate (40e).  
Methyl 3-(5-chloro-6-hydroxy-2-oxobenzo[d]oxazol-3(2H)-yl)propanoate 39 (100 mg, 0.37 
mmol), benzyl bromide (76 mg, 0.44 mmol) and potassium carbonate (102 mg, 0.74 mmol) 
were mixed in acetone (5 mL) and stirred at 70 °C for 15 h.  The solvent was evaporated in 
vacuo and the residue purified by chromatography (silica gel, 200-300 mesh) eluting with 
petroleum ether / ethyl acetate (5:1, 300 mL) to give the title compound (58 mg, 44 %).  
LCMS:  MH+ 362/364, retention time 1.67 min (method A). 
 
Methyl 3-[5-chloro-2-oxo-6-(pyridin-2-ylmethoxy)-2,3-dihydro-1,3-benzoxazol-3-
yl]propanoate (40f).  To methyl 3-(5-chloro-6-hydroxy-2-oxobenzo[d]oxazol-3(2H)-
yl)propanoate 39 (300 mg, 1.1 mmol) in toluene (10 mL) were added pyridin-2-ylmethanol 
(121 mg, 1.1 mmol), DEAD (192 mg, 1.1 mmol) and triphenylphosphine (290 mg, 1.1 mmol) 
and the mixture stirred at ambient temperature for 15 h.  The solvent was evaporated and the 
residue purified by chromatography (silica gel, 200-300 mesh, 15 g), eluting with petroleum 
ether / ethyl acetate (1:1) to give the title compound as a yellow oil (135 mg, 34 %).  LCMS:  
MH+ 363/365, retention time 1.51 min (method A).  
 
(R)-ethyl 3-(5-chloro-6-(1-(oxazol-2-yl)ethoxy)-2-oxobenzo[d]oxazol-3(2H)-yl)propanoate 
(40h).  To a stirred solution of ethyl 3-(5-chloro-6-hydroxy-2-oxobenzo[d]oxazol-3(2H)-
yl)propanoate 39 (700 mg, 2.45 mmol) in DMF (20 mL) were added potassium carbonate 
(676 mg, 4.9 mmol) and 1-(oxazol-2-yl)ethyl methanesulfonate 83 (468 mg, 2.45 mmol).  
The tube was sealed and heated at 60 °C for 3 h.  The reaction was cooled, filtered through 
  
Celite™.  The filtrate was diluted with cool water (300 mL) and the mixture extracted with 
ethyl acetate (3x 100 mL).  The combined organic phases were dried (sodium sulphate) and 
concentrated under reduced pressure.  The residue was purified by chromatography (silica 
gel) eluting with ethyl acetate / hexane (1:1).  The resulting racemic compound was further 
purified by chiral HPLC (column: OY-H, elutent: 0.5% diethylamine in methanol, flow rate 
30 mL /min) to give the title compound (peak 1) as an off-white solid (50 mg, 5 %) and (S)-
ethyl 3-(5-chloro-6-(1-(oxazol-2-yl)ethoxy)-2-oxobenzo[d]oxazol-3(2H)-yl)propanoate (peak 
2, 30 mg, 3%). 
(R)-ethyl 3-(5-chloro-6-(1-(oxazol-2-yl)ethoxy)-2-oxobenzo[d]oxazol-3(2H)-yl)propanoate 
LCMS:  MH+ 381, retention time 2.30  min (method D).  Chiral SFC: retention time 2.98 
min, e.e. 99.0 % (method J). 
(R)-ethyl 3-(5-chloro-6-(1-(oxazol-2-yl)ethoxy)-2-oxobenzo[d]oxazol-3(2H)-yl)propanoate  
Chiral SFC: retention time 3.14  min, e.e. 93.5 % (method J). 
 
 
(R)-ethyl 3-(5-chloro-2-oxo-6-(1-(pyrimidin-2-yl)ethoxy)benzo[d]oxazol-3(2H)-
yl)propanoate (40i).  To a stirred solution of ethyl 3-(5-chloro-6-hydroxy-2-
oxobenzo[d]oxazol-3(2H)-yl)propanoate 39 (800 mg, 2.80 mmol) in DMF (20 mL) were 
added potassium carbonate (773 mg,  5.60 mmol) and 1-(pyrimidin-2-yl)ethyl 
methanesulfonate
24 
(566 mg, 2.80 mmol) in a single portion.  The tube was sealed and heated 
at 60 °C for 3 h.  The reaction was cooled, filtered through Celite™.  The filtrate was diluted 
with aqueous ammonium chloride (20 %, 200 mL) and the mixture extracted with ethyl 
acetate (3x 50 mL).  The combined organic phases were dried (sodium sulphate) and 
concentrated under reduced pressure.  The residue was purified by chromatography (silica 
gel) eluting with ethyl acetate / hexane (1:1).  The resulting racemic compound was further 
  
purified by chiral HPLC (column: IC, elutent: 0.5% diethylamine in methanol) to give the 
title compound (peak 1) as an off-white solid (200 mg, 18 %) (S)-ethyl 3-(5-chloro-2-oxo-6-
(1-(pyrimidin-2-yl)ethoxy)benzo[d]oxazol-3(2H)-yl)propanoate (peak 2, 200 mg, 18 %). 
(R)-ethyl 3-(5-chloro-2-oxo-6-(1-(pyrimidin-2-yl)ethoxy)benzo[d]oxazol-3(2H)-
yl)propanoate LCMS:  MH+ 392, retention time 2.11  min (method D).  Chiral SFC: 
retention time 3.52 min, e.e. 100 % (method K). 
(S)-ethyl 3-(5-chloro-2-oxo-6-(1-(pyrimidin-2-yl)ethoxy)benzo[d]oxazol-3(2H)-
yl)propanoate  Chiral SFC: retention time 4.32 min, e.e. 89.4 % (method K). 
 
Methyl 3-{5-chloro-2-oxo-6-[1-(pyridazin-3-yl)ethoxy]-2,3-dihydro-1,3-benzoxazol-3-
yl}propanoate (40j).  Methyl 3-(5-chloro-6-hydroxy-2-oxobenzo[d]oxazol-3(2H)-
yl)propanoate 39 (236 mg, 0.87 mmol), 1-(pyridazin-3-yl)ethyl methanesulfonate 84 (160 
mg, 0.79 mmol) and potassium carbonate (142 mg, 1.03 mmol) were mixed in acetonitrile (5 
mL) and the mixture stirred at 72 °C for 16 h.  The solvent was evaporated to give crude title 
compound as a yellow oil (380 mg, purity 60 %).  LCMS:  MH+ 378/380, retention time 1.87 
min (method A). 
 
3-{5-Chloro-6-[(1R)-1-(4-methylpyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-
yl}propanoate (40k).  To methyl 3-(5-chloro-6-hydroxy-2-oxobenzo[d]oxazol-3(2H)-
yl)propanoate 39 (316 mg, 1.16 mmol) in THF (20 mL) were added (S)-1-(4-methylpyridin-
2-yl)ethanol 85 (160 mg, 1.16 mmol), DEAD (201 mg, 1.16 mmol) and triphenylphosphine 
(304 mg, 1.16 mmol) and the mixture stirred at ambient temperature for 16 h.  The solvent 
was evaporated in vacuo and the residue purified by chromatography (silica gel, 200-400 
mesh, 20 g), eluting with petroleum ether / ethyl acetate (9:1) to give the title compound as a 
yellow oil (130 mg, 28 %).  LCMS:  MH+ 391, retention time 1.57 min (method A).  
  
 
Methyl 3-{5-chloro-6-[(1R)-1-(5-methylpyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-1,3-
benzoxazol-3-yl}propanoate (40l).  A  mixture of methyl 3-(5-chloro-6-hydroxy-2-
oxobenzo[d]oxazol-3(2H)-yl)propanoate 39 (190 mg, 0.73 mmol), (S)-1-(5-methylpyridin-2-
yl)ethanol 86 (100 mg, 0.73 mmol), DEAD (127 mg, 0.73 mmol) and triphenylphosphine 
(191 mg, 0.73 mmol)  in THF (10 mL) was heated at 45 °C for 14 h.  The solvent was 
evaporated in vacuo and the residue purified by chromatography (silica gel), eluting with 
petroleum ether / ethyl acetate (9:1, 7:1, 5:1 and 4:1) to give the title compound as a yellow 
oil (125 mg, 45 %).  LCMS:  MH+ 391, retention time 1.63 min (method A).  
 
Methyl 3-{5-chloro-6-[1-(5-chloropyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-1,3-benzoxazol-3-
yl}propanoate (40m).  Methyl 3-(5-chloro-6-hydroxy-2-oxobenzo[d]oxazol-3(2H)-
yl)propanoate 39 (140 mg, 0.51 mmol), 1-(5-chloropyridin-2-yl)ethyl methanesulfonate 87 
(121 mg, 0.51 mmol) and potassium carbonate (70 mg, 0.51 mmol) were mixed in 
acetonitrile (10 mL) and the mixture stirred at 60 °C for 16 h.  The reaction was cooled and 
filtered and the solvent was evaporated in vacuo to give crude title compound as a yellow oil 
(210 mg).  LCMS:  MH+ 411, retention time 1.66 min (method A). 
 
Methyl 3-{5-chloro-6-[(1R)-1-(5-fluoropyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-1,3-
benzoxazol-3-yl}propanoate (40n).  A  mixture of methyl 3-(5-chloro-6-hydroxy-2-
oxobenzo[d]oxazol-3(2H)-yl)propanoate 39 (153 mg, 0.56 mmol), (S)-1-(5-fluoropyridin-2-
yl)ethanol (80 mg, 0.56 mmol), DEAD (98 mg, 0.56 mmol) and triphenylphosphine (146 mg, 
0.56 mmol)  in THF (10 mL) was heated at 50 °C for 16 h.  The solvent was evaporated in 
vacuo and the residue purified by chromatography (silica gel), eluting with petroleum ether / 
  
ethyl acetate (12:1, 9:1, 7:1, and 6:1) to give the title compound as a yellow oil (120 mg, 54 
%).  LCMS:  MH+ 395, retention time 1.66 min (method A). 
 
Methyl 3-{5-chloro-6-[(1R)-1-(6-methylpyridin-2-yl)ethoxy]-2-oxo-2,3-dihydro-1,3-
benzoxazol-3-yl}propanoate (40o).  A  mixture of methyl 3-(5-chloro-6-hydroxy-2-
oxobenzo[d]oxazol-3(2H)-yl)propanoate 39 (190 mg, 0.73 mmol), (S)-1-(6-methylpyridin-2-
yl)ethanol (100 mg, 0.73 mmol), DEAD (127 mg, 0.73 mmol) and triphenylphosphine (191 
mg, 0.73 mmol)  in THF (20 mL) was stirred at  ambient temperature for 16 h.  The solvent 
was evaporated in vacuo and the residue purified by chromatography (silica gel), eluting with 
petroleum ether / ethyl acetate (10:1, 7:1, 5:1, and 4:1) to give the title compound as a yellow 
oil (110 mg, 41 %).  LCMS:  MH+ 391, retention time 1.58 min (method A). 
 
7-Bromo-6-chloro-2H-benzo[b][1,4]oxazin-3(4H)-one (42).  To 2-amino-5-bromo-4-
chlorophenol 41 (2.0 g, 8.99 mmol) in DMF (80 mL) at  0 °C was added 2-chloroacetyl 
chloride (1.1 g, 9.89 mmol) and the mixture stirred at 0 °C for 1 h.  Potassium acetate (2.5 g, 
17.98 mmol) was added and the reaction stirred at ambient temperature for 16 h.   Water (100 
mL) was added and the resulting brown solid isolated by filtration to give the title compound 
as a brown solid (1.94 g, 82 %).  LCMS:  MH+ 261, retention time 1.59 min (method B). 
 
3-(7-Bromo-6-chloro-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)propanenitrile (43).  To 7-
bromo-6-chloro-2H-benzo[b][1,4]oxazin-3(4H)-one 42 (1.94 g, 7.39 mmol) in acetonitrile 
(100 mL) were added acrylonitrile (0.78 g, 14.8 mmol) and potassium carbonate (2.04 g, 14.8 
mmol) and the reaction stirred at 70 °C for 16 h.   The solvent was evaporated and water (50 
mL) added to the residue.  The mixture was extracted with ethyl acetate (3x 50 mL), the 
combined organics dried (sodium sulphate) and concentrated to give the title compound as a 
  
light brown solid (2.1g, 90 %).  
1
H NMR (CDCl3) 7.30 (s, 1H), 7.11 (s, 1H), 4.65 (s, 2H), 
4.21 (t, J = 7.0Hz, 2H), 2.80 (t, J = 7.0Hz, 2H). 
 
Methyl 3-(7-bromo-6-chloro-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)propanoate (44).  To 
3-(7-bromo-6-chloro-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)propanenitrile 43 (2.1 g, 6.66 
mmol) in methanol (100 mL) was added concentrated hydrochloric acid (10 mL) and the 
reaction heated at 90 °C for 16 h.  The solvent was evaporated and water (100 mL) added to 
the residue.  The mixture was extracted with ethyl acetate (3x 80 mL), the combined organics 
dried (sodium sulphate) and purified by chromatography (silica gel, 200-300 mesh, 20 g), 
eluting with petroleum ether / ethyl acetate (20:1) to give the title compound as a yellow solid 
(1.2 g, 52 %).  LCMS:  MH+ 349, retention time 1.59 min (method A). 
 
Methyl 3-(6-chloro-3-oxo-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-
benzo[b][1,4]oxazin-4(3H)-yl)propanoate (45).  To methyl 3-(7-bromo-6-chloro-3-oxo-2H-
benzo[b][1,4]oxazin-4(3H)-yl)propanoate 44 (1.2 g, 3.44 mmol) in dioxane (100 mL) were 
added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.62 g, 10.3 mmol), [1,1'-
Bis(diphenylphosphino)ferrocene]palladium(II) dichloride (126 mg, 0.17 mmol) and 
potassium acetate (675 mg, 6.88 mmol) and the mixture stirred at 100 °C under an argon 
atmosphere for 16 h.  The solvent was evaporated, water (100 mL) added to the residue and 
the mixture extracted with ethyl acetate (3x 80 mL).  The combined extracts were dried 
(sodium sulphate) and purified by chromatography (silica gel, 200-300 mesh, 10 g), eluting 
with petroleum ether / ethyl acetate (10:1) to give the crude title compound as a yellow oil 
(1.61g).  LCMS:  MH+ 396, retention time 1.77 min (method A). 
 
  
Methyl 3-(6-chloro-7-hydroxy-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)propanoate (46).  To 
methyl 3-(6-chloro-3-oxo-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-
benzo[b][1,4]oxazin-4(3H)-yl)propanoate 45 (1.6 g, 3.44 mmol) in THF (40 mL) were added 
acetic acid (4 mL) and hydrogen peroxide (30% solution, 5 mL) and the reaction stirred at 
ambient temperature for 3 h.    The reaction was poured into water (20 mL) and extracted 
with ethyl acetate (3x 5 mL).  The combined organics were dried (sodium sulphate) and 
purified by chromatography (silica gel, 200-300 mesh, 10 g), eluting with petroleum ether / 
ethyl acetate (4:1) to give the title compound as a white solid (0.49 g, 42 %).  LCMS:  MH+ 
286, retention time 1.37 min (method A). 
 
Methyl 3-{6-chloro-3-oxo-7-[(1R)-1-(pyridin-2-yl)ethoxy]-3,4-dihydro-2H-1,4-benzoxazin-4-
yl}propanoate (47).  To methyl 3-(6-chloro-7-hydroxy-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-
yl)propanoate 46 (116 mg,   0.41 mmol) in toluene (10 mL) were added (S)-1-(pyridin-2-
yl)ethanol (50 mg, 0.41 mmol), triphenyl phosphine (161 mg, 0.62 mmol) and DEAD (107 
mg, 0.62 mmol) and the mixture stirred at ambient temperature for 2 h.  The solvent was 
evaporated and the residue purified by chromatography (silica gel, 200-300 mesh, 2 g), 
eluting with petroleum ether / ethyl acetate (4:1 to 3:1) to give the crude title compound as a 
white solid (0.27 g).  LCMS:  MH+ 391, retention time 1.54 min (method A). 
 
Ethyl 3-(6-chloro-5-methoxy-1H-indol-1-yl)propanoate (49).  6-chloro-5-methoxy-1H-
indole
25
 48 (2.23g, 12.3 mmol), ethyl acrylate (1.48 g, 14.8mmol) and potassium phosphate 
(653 mg, 3.0 mmol) were mixed in acetonitrile (50 mL) and the reaction stirred at ambient 
temperature for 18 h.  The reaction was filtered and the filtrate reduced to dryness to give 
crude title compound as a yellow oil (2.52g).  This was used directly in the next step without 
further purification.  LCMS:  MH+ 282/284, retention time 1.63 min (method A). 
  
 
Ethyl 3-(6-chloro-5-hydroxy-1H-indol-1-yl)propanoate (50).  Ethyl 3-(6-chloro-5-methoxy-
1H-indol-1-yl)propanoate 49 (crude, 2.52 g) and aluminium chloride (4.0 g, 26.9 mmol) were 
dissolved in toluene (20 mL)  and the mixture stirred at 100 °C for 15 min.  The reaction was 
cooled to 0 °C and water (100 mL) added drop-wise.  The mixture was extracted with ethyl 
acetate (5x 20 mL) and the combined organic phases dried (sodium sulphate).  The solvent 
was evaporated and the residue purified by chromatography (silica gel, 200-300 mesh, 12 g), 
eluting with petroleum ether / ethyl acetate (5:1) to give the title compound as a black oil (1.1 
g, 33% over 2 steps).  LCMS:  MH+ 268/270, retention time 1.47 min (method A). 
 
Ethyl 3-(5-bromo-6-chloro-1H-indazol-1-yl)propanoate (53).  5-bromo-6-chloro-1H-indazole 
52 (2.0 g, 8.7 mmol), ethyl acrylate (955 mg, 9.54 mmol) and DBU (1.45 g, 9.54 mmol) were 
mixed in acetonitrile (20 mL) and the reaction stirred at ambient temperature for 5 h.  The 
solvent was evaporated and the residue purified by chromatography (silica gel, 200-300 
mesh, 4 g), eluting with petroleum ether / ethyl acetate (6:1, 200 mL) to give the title 
compound as a yellow oil (1.0 g, 35 %).  
1
H NMR (CDCl3) 8.00 (s, 1H), 7.94 (d, J = 0.9, 1H), 
7.68 (s, 1H), 4.62 (t, J = 6.6Hz, 2H), 4.11 (q, J = 7.1Hz, 2H), 2.98 (t, J = 6.6Hz, 2H), 1.21 (t, J 
= 7.1Hz, 3H). 
 
Ethyl 3-(6-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-1-
yl)propanoate (54).  To ethyl 3-(5-bromo-6-chloro-1H-indazol-1-yl)propanoate 53 (0.75 g, 
2.36 mmol) ) in dioxane (50 mL) were added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-
dioxaborolane) (1.8 g, 7.09 mmol), [1,1'-Bis(diphenylphosphino)ferrocene]palladium(II) 
dichloride (86 mg, 0.12 mmol) and potassium acetate (463 mg, 4.72 mmol) and the mixture 
stirred at 100 °C under an argon atmosphere for 16 h.  The solvent was evaporated and the 
  
residue purified by chromatography (silica gel, 200-300 mesh, 20 g), eluting with petroleum 
ether / ethyl acetate (10:1) to give the crude title compound as a yellow oil (1.5 g).  LCMS:  
MH+ 379, retention time 1.81 min (method A). 
 
Ethyl 3-(6-chloro-5-hydroxy-1H-indazol-1-yl)propanoate (55).  To ethyl 3-(6-chloro-5-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-1-yl)propanoate 54 (1.5 g, 2.36 
mmol) in acetic acid (6 mL) were added THF (6 mL) and hydrogen peroxide (30 % solution, 
2 mL) and the reaction stirred at ambient temperature for 2 h.  The solvent was evaporated 
and water (10 mL) added to the residue.  The mixture was extracted with ethyl acetate (3x 10 
mL) and the combined organics dried (sodium sulphate).  The residue was purified by 
chromatography (silica gel, 200-300 mesh, 20 g), eluting with petroleum ether / ethyl acetate 
(10:1 to 1:1) to give the title compound as a yellow solid (0.5 g, 79 %).  LCMS:  MH+ 269, 
retention time 1.44 min (method A). 
 (R)-ethyl 3-(5-chloro-6-(1-(5-methylpyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate 
%).  
1
H NMR (D6-DMSO) 8.41 (d, J= 0.9Hz, 1H), 8.06 (s, 1H), 7.62 (dd, J = 7.9Hz, J = 
1.5Hz, 1H), 7.39 (d, J = 7.7Hz, 1H), 7.34 (s, 1H), 5.72 (q, J = 6.7Hz, 1H), 4.40 (q, J = 7.2Hz, 
2H), 3.16 (t, J = 7.1Hz, 2H), 2.81 (t, J = 7.3Hz, 2H), 2.27 (s, 3H), 1.66 (d, J = 6.4Hz, 3H), 
1.14 (t, J = 7.1Hz, 3H).  LCMS:  MH+ 389, retention time 2.56 min (method D). 
  
Ethyl 3-{6-chloro-5-[(1R)-1-(pyridin-2-yl)ethoxy]-1H-indazol-1-yl}propanoate (56).  Ethyl 
3-(6-chloro-5-hydroxy-1H-indazol-1-yl)propanoate 55 (90 mg, 0.33 mmol) in toluene (10 
mL) were added (S)-1-(pyridin-2-yl)ethanol (42 mg, 0.33 mmol), triphenyl phosphine (130 
mg, 0.50 mmol) and DEAD (87 mg, 0.50 mmol) and the mixture stirred at ambient 
temperature for 16 h.  The solvent was evaporated and the residue purified by 
chromatography (silica gel, 200-300 mesh, 5 g), eluting with petroleum ether / ethyl acetate 
  
(10:1 to 3:1) to give the crude title compound as a yellow oil (0.1 g).  LCMS:  MH+ 374, 
retention time 1.65 min (method A). 
 
1-(5-Methylpyridin-2-yl)ethyl methanesulfonate  (63b).  To a stirred solution of 1-(5-
methylpyridin-2-yl)ethanol (100 mg, 0.729 mmol) in DCM (5 mL) at 0 °C was added 
triethylamine (110 mg, 1.0 mmol) and the reaction stirred for 15 min at 0 °C.  Mesyl chloride 
(91.4 mg, 0.802 mmol) was added drop-wise and stirring continued for 2 h.  The reaction was 
washed with brine, the aqueous extracted with DCM.  The combined organic phases were 
washed with brine, dried (sodium sulphate) and concentrated to give the crude title compound 
as a brown oil (150 mg).  Used without further purification.   
 
(R)-ethyl 3-(5-chloro-6-(1-(5-methylpyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate 
(64b).  Potassium carbonate (192 mg, 1.39 mmol) was added to a stirred suspension of ethyl 
3-(5-chloro-6-hydroxybenzo[d]isoxazol-3-yl)propanoate
20
 62a (250 mg, 0.929 mmol) in 
DMF (5 mL) and the mixture stirred for 30 min.  1-(5-Methylpyridin-2-yl)ethyl 
methanesulfonate  63b (220mg, 1.02 mmol) was dissolved in DMF (5 mL) and added to the 
mixture.  The reaction was heated in a sealed tube at 80 °C overnight.  The reaction was 
filtered through Celite™, the Celite washed with ethyl acetate (60 mL) and the filtrate diluted 
with saturated ammonium chloride solution.  The mixture was extracted with ethyl acetate 
(3x 50 mL), the combined organic phases washed with brine, dried (sodium sulphate) and 
concentrated.  The residue was purified by chromatography eluting with ethyl acetate / 
petroleum ether (3:17) to give the racemic compound as an off-white solid.  The isomers 
were separated by chiral SFC (column: Chiralpak AD-H (260x 4.6 mm, 5µ, Solvents: CO2 / 
methanol (60:40), flow 4.0 g/min, uv 210 nm) to give the title compound (120 mg, 30 %) and 
  
(S)-ethyl 3-(5-chloro-6-(1-(5-methylpyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate 
(130 mg).  
(R)-ethyl 3-(5-chloro-6-(1-(5-methylpyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate 
1
H NMR (D6-DMSO) 8.40 (d, J = 0.9Hz, 1H), 8.05 (s, 1H),  7.61 (dd, J = 7.9Hz, J = 1.5Hz, 
1H), 7.38 (d, J = 7.7Hz, 1H),  7.34 (s, 1H), 5.71 (q, J = 6.7Hz, 1H), 4.04 (q, J = 7.2Hz, 2H), 
3.15 (t, J = 7.1Hz, 2H), 2.80 (t, J = 7.3Hz, 2H), 2.26 (s, 3H), 1.65 (d, J = 6.4Hz, 3H), 1.13 (t, J 
= 7.1Hz, 3H).  LCMS:  MH+ 389, retention time 2.56 min (method D).  Chiral SFC: retention 
time 2.67 min, e.e. 99.9% (method I). 
(S)-ethyl 3-(5-chloro-6-(1-(5-methylpyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate  
Chiral SFC: retention time 5.18 min, e.e. 99.1% (method I). 
 
(R)-Ethyl 3-(5-chloro-6-(1-(5-chloropyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate 
(64c).  A stirred solution of  potassium carbonate (513 mg, 3.71 mmol) and ethyl 3-(5-chloro-
6-hydroxybenzo[d]isoxazol-3-yl)propanoate 62a (500 mg, 1.85 mmol) in acetonitrile (10 
mL) was treated with 1-(5-chloropyridin-2-yl)ethyl methanesulfonate
26
 63c (524mg, 2. 23 
mmol)  and the reaction was heated at 70 °C for 6 h.  The reaction was filtered through 
Celite™, the Celite washed with ethyl acetate (100 mL) and the filtrate washed with water 
(50 mL) and brine.  The organic phase was dried (sodium sulphate) and concentrated.  The 
residue was triturated with pentane to give the racemic compound as an off-white solid 
(400mg).  The isomers were separated by chiral SFC (column: Chiralpak AD-H (250x 4.6 
mm, 5µ, Solvents: CO2 / 0.5% diethylamine in methanol) to give the title compound (140mg, 
18 %) and (S)-ethyl 3-(5-chloro-6-(1-(5-chloropyridin-2-yl)ethoxy)benzo[d]isoxazol-3-
yl)propanoate (160 mg). 
(R)-ethyl 3-(5-chloro-6-(1-(5-chloropyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate.  
1
H NMR (CDCl3) 8.56 (d, J = 2.2Hz, 1H), 7.66 (m, 2H), 7.44 (d, J= 8.6Hz, 1H), 6.94 (s, 1H),  
  
5.52 (q, J = 6.6Hz, 1H), 4.17 (q, J = 7.2Hz, 2H), 3.21 (t, J = 7.5Hz, 2H), 2.86 (t, J = 7.5Hz, 
2H), 1.78 (d, J = 6.6Hz, 3H), 1.26 (J = 7.1Hz, 3H).  LCMS:  MH+ 409, retention time 2.88 
min (method D).  Chiral SFC: retention time 2.50 min, e.e. 99.8% (method H). 
(S)-ethyl 3-(5-chloro-6-(1-(5-chloropyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate   
Chiral SFC: retention time 1.73 min, e.e. 99.6% (method H). 
 
(R)-methyl 3-(5-chloro-6-(1-(5-fluoropyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoate 
(64d).   To a mixture of methyl 3-(5-chloro-6-hydroxybenzo[d]isoxazol-3-yl)propanoate
20
 62 
(435 mg, 1.7 mmol) in THF (20 mL) were added (1R)-1-(5-fluoropyridin-2-yl)ethan-1-ol 63d 
(200 mg, 1.42 mmol), triphenyl phosphine (559 mg, 2.13 mmol), DEAD (371 mg, 2.13 
mmol) and the reaction stirred at room temperature for 2 h.  The solvent was evaporated and 
the residue purified by chromatography (silica, 200-300  mesh, 10 g) eluting with petroleum 
ether  / ethyl acetate (3 : 1) to give the title compound as a colourless oil (150 mg, 28%).  
LCMS:  MH+ 379, retention time 1.69 min (method A). 
 
5-Chloro-6-methoxybenzo[d]thiazol-2(3H)-one (66).  5-Chloro-6-methoxybenzo[d]thiazol-2-
amine
27
 65 (8.0 g, 37.3 mmol) was dissolved in a mixture of formic acid (25 mL), acetic acid 
(10 mL), hydrochloric acid (36 %, 20 mL) at -10 °C.  A solution of sodium nitrite (2.83 g, 41 
mmol) in water (15 mL) was added drop-wise and the reaction stirred at -10 °C for 1 h before 
allowing the reaction to warm to ambient temperature.  The reaction was then heated at 100 
°C for 18 h.  The cooled reaction was diluted with water (200 mL) and extracted with ethyl 
acetate (5x 50 mL).  The organics were washed with brine (2x 100mL), dried, filtered and the 
solvent evaporated.  The residue was purified by chromatography (silica gel, 200-300 mesh, 
12 g), eluting with ethyl acetate / DCM (1:10, 500 mL) to give the title compound as a grey 
  
solid (2.2 g, 25 %).  
1
H NMR (D6-DMSO) 11.81 (br. s, 1H), 7.50 (s, 1H), 7.12 (s, 1H), 3.34 
(s, 3H).  LCMS:  MH+ 216/218, retention time 1.48 min (method A). 
 
Ethyl 3-(5-chloro-6-methoxy-2-oxobenzo[d]thiazol-3(2H)-yl)propanoate (67).  5-Chloro-6-
methoxybenzo[d]thiazol-2(3H)-one 66 (600 mg, 2.78 mmol), ethyl acrylate (333 mg, 3.33 
mmol), tetraethyl orthosilicate (580 mg, 2.78 mmol) and cesium fluoride (51 mg, 0.33 mmol) 
were mixed in toluene (15 mL) and the reaction heated at 110 °C for 16 h.  The solvent was 
evaporated and the residue purified by chromatography (silica gel, 200-300 mesh, 4 g), 
eluting with petroleum ether / ethyl acetate (2:1, 300 mL) to give the title compound as a 
yellow solid (740 mg, 84 %).  LCMS:  MH+ 316/318, retention time 1.64 min (method A). 
 
Ethyl 3-(5-chloro-6-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-3-yl)propanoate (68).  
Boron tribromide (2.93 g, 11.7 mmol) was added drop-wise at ambient temperature to a 
mixture of ethyl 3-(5-chloro-6-methoxy-2-oxobenzo[d]thiazol-3(2H)-yl)propanoate 67 in 
DCM (15 mL) and the reaction stirred at ambient temperature for 15 h.  The mixture was 
cooled to 0 °C and water (50 mL) added drop-wise.  The mixture was extracted with ethyl 
acetate (3x 50 mL) and the combined organics dried (sodium sulphate).  The solvent was 
evaporated to give the title compound as a yellow solid (580 g, 82 %).  LCMS:  MH+ 
302/304, retention time 1.50 min (method A). 
 
(4-Chloro-3-methoxyphenyl)(methyl)sulfane (71).  To 4-chloro-3-methoxyaniline 70 (10 g, 
63. 5 mmol) in hydrochloric acid (37 %, 13.2 g, 133 mmol) and water (50 mL) at 0 °C was 
added a solution of sodium nitrite (4.38 g, 63.5 mmol) in water (5 mL) and the reaction 
stirred at 0 °C for 30 min.  Sodium methanethiolate (20 % aqueous, 22.25 g, 63.5 mmol) was 
added to the mixture and the reaction warmed to ambient temperature and stirred for 15 min.  
  
The reaction was extracted with ethyl acetate (3x 100 mL), the combined organics dried 
(sodium sulphate) and the residue purified by chromatography (silica gel, 200-300 mesh, 50 
g), eluting with petroleum ether / ethyl acetate (50:1) to give the title compound as a yellow 
oil (7.3 g, 61 %).  
1
H NMR (CDCl3) 7.28 (d, J = 8.1Hz, 1H), 6.84 (d, J = 2.0Hz, 1H), 6.79 
(dd, J = 8.3Hz, J = 2.2Hz, 1H), 3.91 (s, 3H), 2.51 (s, 3H). 
 
4-(5-Chloro-4-methoxy-2-(methylthio)phenyl)-4-oxobutanoic acid (72a).  To (4-chloro-3-
methoxyphenyl)(methyl)sulfane 71 (7.3 g, 38.7 mmol) in DCM (100 mL) were added 
dihydrofuran-2,5-dione (3.87g, 38.7 mmol) and aluminium chloride (5.68 g, 42.6 mmol) and 
the reaction stirred at ambient temperature for 16 h.  Water (20 mL) was added, the solid 
isolated by filtration to give the title compound as a white solid (6.3 g, 56 %).  LCMS:  MH+ 
289, retention time 1.56 min (method A). 
 
Methyl 4-(5-chloro-4-methoxy-2-(methylthio)phenyl)-4-oxobutanoate (72b).  To 4-(5-chloro-
4-methoxy-2-(methylthio)phenyl)-4-oxobutanoic acid 72a (6.3 g, 21.8 mmol) in methanol 
(100 mL) was added thionyl chloride (3.12g, 26.2 mmol) and the mixture stirred at ambient 
temperature for 16 h.  The solvent was evaporated and the residue purified by 
chromatography (silica gel, 200-300 mesh, 20 g), eluting with DCM / methanol (100:1) to 
give the title compound as a white solid (5.2 g, 78 %).  LCMS:  MH+ 303, retention time 
1.67 min (method A). 
 
Methyl 4-(5-chloro-4-methoxy-2-(methylthio)phenyl)-4-(hydroxyimino)butanoate (73).  To 
methyl 4-(5-chloro-4-methoxy-2-(methylthio)phenyl)-4-oxobutanoate 72b (5.2 g, 17.2 mmol) 
in acetonitrile / ethanol (1:1, 100 mL) was added ammonium hydroxide hydrochloride (5.97 
g, 85.9 mmol) and the reaction stirred at 110 °C for 16 h.  The solvent was evaporated and 
  
the residue purified by chromatography (silica gel, 200-300 mesh, 20 g), eluting with DCM / 
methanol (200:1) to give the title compound as a yellow oil (4.5 g, 82 %).  LCMS:  MH+ 
318, retention time 1.63 min (method A). 
 
Methyl 3-(5-chloro-6-methoxybenzo[d]isothiazol-3-yl)propanoate (74).  Methyl 4-(5-chloro-
4-methoxy-2-(methylthio)phenyl)-4-(hydroxyimino)butanoate 73 (4.5 g, 14.16 mmol) in 
pyridine / acetic anhydride (1:1, 50 mL) was heated at 120 °C for 16 h.  The solvent was 
evaporated and the residue purified by chromatography (silica gel, 200-300 mesh, 20 g), 
eluting with DCM / methanol (200:1) to give the title compound as a yellow solid (1.57 g, 39 
%).  LCMS:  MH+ 286, retention time 1.73 min (method A). 
 
Methyl 3-(5-chloro-6-hydroxybenzo[d]isothiazol-3-yl)propanoate (75b).  Methyl 3-(5-chloro-
6-methoxybenzo[d]isothiazol-3-yl)propanoate 74 (1.57 g, 5.49 mmol) in hydrobromic acid 
(48%, 30 mL) was heated at 125 °C for 16 h.  The reaction was cooled to room temperature, 
filtered and the solid dried to give crude 3-(5-chloro-6-hydroxybenzo[d]isothiazol-3-
yl)propanoic acid 75a (1.8g).  LCMS:  MH+ 258, retention time 1.28 min (method A). 
To this material  in methanol (50 mL) was added thionyl chloride (784 mg, 6.6mmol) and the 
reaction stirred at ambient temperature for 16 h.   The solvent was evaporated and the residue 
purified by chromatography (silica gel, 200-300 mesh, 20 g), eluting with DCM / methanol 
(30:1) to give the title compound as a purple solid (1.1 g, 52 %).  LCMS:  MH+ 272, 
retention time 1.43 min (method A). 
 
Methyl 3-{5-chloro-6-[(1R)-1-(pyridin-2-yl)ethoxy]-1,2-benzothiazol-3-yl}propanoate (76).  
Methyl 3-(5-chloro-6-hydroxybenzo[d]isothiazol-3-yl)propanoate 75b (200 mg, 0.74 mmol) 
in toluene (20 mL) was treated with (1S)-1-(pyridin-2-yl)ethan-1-ol (91 mg, 0.74 mmol), 
  
triphenyl phosphine (290 mg, 1.10 mmol) and DEAD (192 mg, 1.10 mmol) and the mixture 
stirred at 80 °C for 16 h.  The solvent was evaporated and the residue purified by 
chromatography (silica gel, 200-300 mesh, 10 g), eluting with DCM / methanol (100:1) to 
give the crude title compound as a white solid (0.4 g).  LCMS:  MH+ 377, retention time 1.54 
min (method A). 
 
4-Chloro-5-isobutyl-2-nitrophenol (77).  4-Chloro-3-isobutylphenol 78 (500 mg, 2.71 mmol) 
in acetic acid (10 mL) at room temperature was treated with nitric acid (70 %, 2.2 mL) and 
the reaction stirred at ambient temperature for 2 h.   The reaction was diluted with water and 
extracted with ethyl acetate.  The organic phase was washed with water (100 mL x3) and 
dried (magnesium sulphate) and the solvent evaporated in vacuo.  The residue was purified 
by chromatography (silica gel, 200-400 mesh, 40 g) eluting with petroleum ether / ethyl 
acetate (200:1 then 100:1) which gave crude title compound as a yellow oil (420 mg, 68 %).  
1
H NMR (CDCl3) includes 10.30 (s, 1H), 7.98 (s, 1H), 6.88 (s, 1H), 2.51 (d, J = 7.3Hz, 2H), 
1.90 (m, 1H), 0.85 (d, J = 6.8Hz, 6H). 
 
4-Chloro-3-isobutylphenol (78).  1-Chloro-2-isobutyl-4-methoxybenzene 79 (1.69 g, 8.7 
mmol) in DCM (20 mL) was treated with boron tribromide (2.63 g, 10.4 mmol) at room 
temperature and the mixture stirred for 4 h.  Water was added and the mixture extracted with 
DCM.  The organic phase was dried (magnesium sulphate) and the solvent evaporated in 
vacuo.  The residue was purified by chromatography (silica gel, 200-400 mesh, 30 g) eluting 
with petroleum ether / ethyl acetate (20:1) to give the title compound as a yellow oil (1.1 g, 
74 %).  
1
H NMR (CDCl3) 7.06 (d, J = 8.4Hz, 1H), 6.55 (d, J = 3.0Hz, 1H), 6.50 (dd, J = 
8.4Hz, J = 3.0Hz, 1H), 2.42 (d, J = 7.1Hz, 2H), 1.85 (m, 1H), 0.82 (6H, J = 6.6Hz, d). 
 
  
1-Chloro-2-isobutyl-4-methoxybenzene (79).  1-Chloro-4-methoxy-2-(2-methylprop-1-en-1-
yl)benzene 80 (2.59 g, 12.7 mmol) and platinum dioxide (200 mg, 1.0 mmol) in toluene (30 
mL) were stirred at ambient temperature under 1 Atm. of hydrogen for 16 h.  The mixture 
was filtered and the solvent evaporated in vacuo.  The residue was purified by 
chromatography (silica gel, 200-400 mesh, 30 g) eluting with petroleum ether / ethyl acetate 
(20:1) to give the title compound as a colourless oil (1.6 g, 64 %).  
1
H NMR (CDCl3) 7.25 (d, 
J = 8.6Hz, 1H), 6.74 (d, J = 2.9Hz, 1H), 6.71 (dd, J = 8.6Hz, J = 3.2Hz, 1H), 3.81 (s, 3H), 
2.59 (d, J =7.3Hz, 2H), 2.00 (m, 1H), 0.96 (d, J = 6.8Hz, 6H). 
 
1-Chloro-4-methoxy-2-(2-methylprop-1-en-1-yl)benzene (80).  To 
isopropyltriphenylphosphonium iodide (10.93 g, 25.2 mmol) in THF (50 mL) at room 
temperature was added sodium hydride (60%, 1 g, 27.5 mmol) and the mixture stirred for 1 h. 
2-Chloro-5-methoxybenzaldehyde (3.93 g, 22,9 mmol) was added to the reaction and stirring 
continued for 16 h.  Water was added and the mixture extracted with ethyl acetate.  The 
organic phase was dried (magnesium sulphate) and the solvent evaporated in vacuo.  The 
residue was purified by chromatography (silica gel) eluting with petroleum ether / ethyl 
acetate (40:1) to give the title compound as a brown oil (2.5 g, 55 %).  
1
H NMR (CDCl3) 7.28 
– 7.23 (m, 2H), 6.80 (d, J = 3.0Hz, 1H), 6.72 (dd, J = 8.8, J = 3.0, 1H), 6.27 (s, 1H), 3.80 (s, 
3H), 1.95, (s, 3H), 1.81 (s, 3H). 
 
5-Chloro-4-cyclopropoxy-2-methoxyaniline (81).  Iron (421 mg, 7.53 mmol) was added 
portion-wise to a solution of 1-chloro-2-cyclopropoxy-4-methoxy-5-nitrobenzene 82 (609 
mg, 2.51 mmol) in a mixture of water (10 mL) and acetic acid (10 mL) at 80 °C and the 
mixture stirred at 80 °C for a further 1 h after completion of the addition.  The reaction was 
cooled to room temperature, filtered and the filtrate extracted with ethyl acetate (4x 50 mL).  
  
The combined organics were reduced to dryness in vacuo.  The residue was redissolved in 
ethyl acetate (50mL), washed with brine (2x 100mL) dried (sodium sulphate) and the solvent 
evaporated in vacuo to give the title compound as a black oil (470 mg, 88%).  LCMS:  MH+ 
214 / 216, retention time 1.50 min (method A). 
 
1-Chloro-2-cyclopropoxy-4-methoxy-5-nitrobenzene (82).  Cyclopropanol (314 mg, 5.4 
mmol) was dissolved in DMF (10 mL) at 0 °C and treated with sodium hydride (60%, 360 
mg, 9.0 mmol) added portion-wise.  The mixture was stirred at 0 °C for 30 min.   1,2-
dichloro-4-methoxy-5-nitrobenzene (1.0 g, 4.5 mmol) was added in a single portion and the 
mixture stirred at 40 °C for 45 min, before cooling to ambient temperature.  Water (30 mL) 
was added slowly and the resulting mixture extracted with ethyl acetate (4x 20 mL).  The 
combined organic phases were concentrated in vacuo and the residue purified by 
chromatography (silica gel, 12 g) eluting with petroleum ether / ethyl acetate (30:1, 250 mL) 
to give the title compound as a pale yellow solid (610 mg, 56%).  LCMS:  MH+ 244 / 246, 
retention time 1.69 min (method A). 
 
1-(Oxazol-2-yl)ethyl methanesulfonate (83).  To a stirred solution of 1-(oxazol-2-yl)ethanol 
(650 mg, 5.75 mmol) in DCM (10 mL) at 0 °C was added triethylamine (1.25 mL, 8.62 
mmol) and the mixture stirred for 10 min.  To this was added mesyl chloride (0.53 mL, 6.90 
mmol) and the reaction stirred for 3 h at between 5 and 20 °C.  The reaction was quenched by 
addition of brine (200 mL) and the mixture extracted with DCM (3x 15 mL).  The combined 
organic phases were dried (sodium sulphate) and concentrated under reduced pressure to give 
crude title compound as a pale yellow oil (700 mg).  This material was used without further 
purification or analysis due to instability. 
 
  
1-(Pyridazin-3-yl)ethyl methanesulfonate (84).  1-(Pyridazin-3-yl)ethanol
28
 (200 mg, 1.61 
mmol) and triethylamine (212 mg, 2.09 mmol) were mixed in DCM (8 mL) at 0 °C.  To this 
was added drop-wise a solution of mesyl chloride (203 mg, 1.77 mL) dissolved in DCM (2 
mL) and the reaction was stirred at 0 °C for 1h.  The solvent was evaporated and the residue 
purified by chromatography (silica gel, 200-300 mesh, 4 g) eluting with petroleum ether / 
ethyl acetate (1:2, 150 mL) to give the title compound as a pale yellow oil (160 mg, 49 %).  
LCMS:  MH+ 203, retention time 1.03 min (method A). 
 
(S)-1-(4-Methylpyridin-2-yl)ethanol (85).  To R-CBS (3.7 mL, 3.7 mmol) in THF (20 mL) at 
0 °C was added borane.dimethyl sulphide solution (2M, 1.85 mL, 3.7 mmol) and the mixture 
stirred at 0 °C for 1 h.   1-(4-Methylpyridin-2-yl)ethanone (400  mg, 2.96 mmol) was added 
and the reaction stirred at ambient temperature for 2 h.  Methanol (15 mL) was added and the 
solvent evaporated in vacuo.  The residue was purified by chromatography (silica gel, 200-
400 mesh, 20 g) eluting with DCM / methanol (20:1 then 10:1) to give the title compound as 
a yellow oil (160 mg, 40 %).  LCMS:  MH+ 138, retention time 0.42 min (method A). 
 
 (S)-1-(5-Methylpyridin-2-yl)ethanol (86).  To R-CBS (3.7 mL, 3.7 mmol) in THF (10 mL) at 
0 °C was added borane.dimethyl sulphide solution (2M, 1.85 mL, 3.7 mmol) and the mixture 
stirred at 0 °C for 1 h.   1-(5-Methylpyridin-2-yl)ethanone (400  mg, 2.96 mmol) was added 
and the reaction stirred at ambient temperature for 16 h.  Water (50 mL) was added and the 
mixture extracted with ethyl acetate (2x 50 mL).  The combined organic phases were dried 
(magnesium sulphate) and the solvent evaporated in vacuo.  The residue was purified by 
chromatography (silica gel) eluting with petroleum ether / ethyl acetate (9:1, 7:1, 5:1) to give 
the title compound as a colourless oil (110 mg, 28 %).  LCMS:  MH+ 138, retention time 
1.34 min (method A). 
  
 
1-(5-Chloropyridin-2-yl)ethyl methanesulfonate (87).  A mixture of 1-(5-chloropyridin-2-
yl)ethanol (390 mg, 1.2 mmol), mesyl chloride (206 mg, 1.8 mmol) and triethylamine (180 
mg, 1.8 mmol) in DCM was stirred at ambient temperature for 6 h.  the solvent was 
evaporated in vacuo and the residue purified by chromatography (silica gel, 200-400 mesh, 
20 g), eluting with petroleum ether / ethyl acetate (7:1 then 4:1) to give the title compound as 
a yellow oil (121 mg, 21 %).  LCMS:  MH+ 236, retention time 1.41 min (method A). 
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